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How is it that we know so little, given that we have so much information? 
-Noam Chomsky- 
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ABSTRACT 
 
In this thesis, two separate single nucleotide polymorphism (SNP) genotyping techniques 
were set up at the Finnish Genome Center, pooled genotyping was evaluated as a 
screening method for large-scale association studies, and finally, the former approaches 
were used to identify genetic factors predisposing to two distinct complex diseases by 
utilizing large epidemiological cohorts and also taking environmental factors into account.  
 
The first genotyping platform was based on traditional but improved restriction-fragment-
length-polymorphism (RFLP) utilizing 384-microtiter well plates, multiplexing, small 
reaction volumes (5 µl), and automated genotype calling. We participated in the 
development of the second genotyping method, based on single nucleotide primer 
extension (SNuPeTM by Amersham Biosciences), by carrying out the alpha- and beta tests 
for the chemistry and the allele-calling software. Both techniques proved to be accurate, 
reliable, and suitable for projects with thousands of samples and tens of markers. 
 
Pooled genotyping (genotyping of pooled instead of individual DNA samples) was 
evaluated with Sequenom’s MassArray MALDI-TOF, in addition to SNuPeTM and PCR-
RFLP techniques. We used MassArray mainly as a point of comparison, because it is 
known to be well suited for pooled genotyping. All three methods were shown to be 
accurate, the standard deviations between measurements being 0.017 for the MassArray, 
0.022 for the PCR-RFLP, and 0.026 for the SNuPeTM. The largest source of error in the 
process of pooled genotyping was shown to be the volumetric error, i.e., the preparation of 
pools. We also demonstrated that it would have been possible to narrow down the genetic 
locus underlying congenital chloride diarrhea (CLD), an autosomal recessive disorder, by 
using the pooling technique instead of genotyping individual samples. Although the 
approach seems to be well suited for traditional case-control studies, it is difficult to apply 
if any kind of stratification based on environmental factors is needed. Therefore we chose 
to continue with individual genotyping in the following association studies. 
 
Samples in the two separate large epidemiological cohorts were genotyped with the PCR-
RFLP and SNuPeTM techniques. The first of these association studies concerned various 
pregnancy complications among 100,000 consecutive pregnancies in Finland, of which we 
genotyped 2292 patients and controls, in addition to a population sample of 644 blood 
donors, with 7 polymorphisms in the potentially thrombotic genes. In this thesis, the 
analysis of a sub-study of pregnancy-related venous thromboses was included. We showed 
that the impact of factor V Leiden polymorphism on pregnancy-related venous 
ABSTRACT 
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thrombosis, but not the other tested polymorphisms, was fairly large (odds ratio 11.6; 95% 
CI 3.6-33.6), and increased multiplicatively when combined with other risk factors such as 
obesity or advanced age. Owing to our study design, we were also able to estimate the 
risks at the population level. 
 
The second epidemiological cohort was the Helsinki Birth Cohort of men and women who 
were born during 1924-1933 in Helsinki. The aim was to identify genetic factors that 
might modify the well known link between small birth size and adult metabolic diseases, 
such as type 2 diabetes and impaired glucose tolerance. Among ~500 individuals with 
detailed birth measurements and current metabolic profile, we found that an 
insertion/deletion polymorphism of the Angiotensin converting enzyme (ACE) gene was 
associated with the duration of gestation, and weight and length at birth. Interestingly, the 
ACE insertion allele was also associated with higher indices of insulin secretion 
(p=0.0004) in adult life, but only among individuals who were born small (those among 
the lowest third of birth weight). Likewise, low birth weight was associated with higher 
indices of insulin secretion (p=0.003), but only among carriers of the ACE insertion allele. 
The association with birth measurements was also found with a common haplotype of the 
glucocorticoid receptor (GR) gene. Furthermore, the association between short length at 
birth and adult impaired glucose tolerance was confined to carriers of this haplotype 
(p=0.007). These associations exemplify the interaction between environmental factors 
and genotype, which, possibly due to altered gene expression, predisposes to complex 
metabolic diseases. Indeed, we showed that the common GR gene haplotype associated 
with reduced mRNA expression in thymus of three individuals (p=0.0002).  
INTRODUCTION 
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INTRODUCTION 
 
Although the human genome is highly conserved, approximately 3 million nucleotides 
vary when genomic sequences of two random individuals are compared (Kruglyak and 
Nickerson 2001). The most common variation in the human genome is a biallelic single 
nucleotide polymorphism (SNP), which by definition differs between individuals only by 
one base pair (bp) with a minor allele frequency of at least 1%. The facts that SNPs are 
abundant, genetically stable, and relatively easy to detect have made them valuable 
markers for gene mapping purposes (Syvänen 2001). After the release of the human 
genome sequence, the cataloging of SNPs has been a major task (Lander et al. 2001, 
Venter et al. 2001, International Human Genome Sequencing Consortium 2004). Indeed, 
there are already 11 million identified SNPs available in public databases. This has 
brought along a vast need of new genotyping technologies to enable the genotyping of a 
large number of markers. There are numerous SNP genotyping techniques available; while 
one specific “standard method” does not exist. However, techniques based on primer 
extension  have become among the most widely applied approaches to genotype SNPs 
(Syvänen et al. 1990).  
 
To obtain the required statistical power the sample sizes in the studies of common, 
multifactorial diseases need to be much larger than in the case of monogenic diseases. 
This has led to a major increase in genotyping costs that has become a bottleneck for many 
researchers. Therefore, more economical applications are urgently needed. Pooled 
genotyping, the genotyping of pooled instead of individual DNA samples, is an approach 
that can save reagent costs, time, and effort considerably. Allele frequencies of separate 
DNA pools (consisting of, for example, patients in one pool and controls in another) can 
be quite accurately estimated by comparing the allele peak height ratios obtained from 
pools of individual heterozygous controls known to carry a 50:50 allelic ratio. This 
approach has been tested with different platforms, e.g., with Sequenom’s MALDI-TOF 
MassArray genotyping system (Le Hellard et al. 2002, Mohlke et al. 2002, Herbon et al. 
2003), but not with SNuPeTM (single nucleotide primer extension) or PCR-RFLP with 
automated genotype calling, the latter of which can be used without any specialized 
instrumentation.  
 
The diseases studied in this thesis are of multifactorial etiology; a variety of environmental 
as well as genetic factors are known to contribute to the onset of these diseases. 
Pregnancy-associated venous thrombosis is the most prevalent cause of maternal death in 
western countries (Greer 1999, Walker 2003). The known risk factors include advanced 
INTRODUCTION 
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age, obesity, non-O blood group, and family history, implying a genetic contribution 
(Rosendaal 1999). Although the effect of the Factor V Leiden and the prothrombin 
polymorphisms have been established, the risks at the population level have been poorly 
characterized. 
 
The association of small body size at birth and adult diseases is well established by a 
number of epidemiological observations (Barker et al. 1989, Lithell et al. 1996, Eriksson 
et al. 2001) and animal research (Langley et al. 1994, Vickers et al. 2000). However, the 
mechanism underlying this phenomenon is uncertain. The link has been explained by the 
fetal programming hypothesis, which proposes that fetal malnutrition or mother’s stress 
result in developmental adaptations that permanently change the structure and function of 
critical organs, and hence the physiology and metabolism of the body, thereby 
predisposing individuals to cardiovascular, metabolic, and endocrine disease in adult life 
(Hales and Barker 1992, Barker 1998, Barker 1999, Hales and Barker 2001). The link has 
also been explained by the shared genetic factors that underlie both of these phenotypes 
(Frayling and Hattersley 2001). On the other hand, the programming effect may be 
affected by the genetic factors, which is the hypothesis that we have tested in this thesis. 
 
Identification of genes underlying monogenic diseases with Mendelian inheritance has 
been very successful in the last decade. However, when complex diseases are considered 
the use of traditional gene mapping approaches has not been very fruitful. It has been 
suggested that family-based linkage-analysis is not powerful enough for identifying 
predisposing genes for complex diseases (Risch and Merikangas 1996, Cardon and Bell 
2001, Tabor et al. 2002). Association analyses are thus increasingly used, which has 
brought along a need of more accurate and efficient genotyping technologies. In addition, 
the lack of environmental factors taken into account in an appropriate study setting, such 
as in prospective cohort studies, has been criticized (Chakravarti and Little 2003, Collins 
2004, Hunter 2005). These aspects have been taken into account in this thesis.  
REVIEW OF THE LITERATURE 
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REVIEW OF THE LITERATURE 
 
1 STRUCTURE OF THE HUMAN GENOME 
 
1.1 Human Genome Project 
A massive effort to sequence the DNA of a whole human genome consisting of 
approximately 3 billion base pairs (bp) and to identify every gene in the human genome 
was officially launched in 1990. This enormous work of the Human Genome Project was 
completed already in 2003; two years earlier than initially planned. In February 2001, 
Nature (Lander et al. 2001) published the sequence and analysis of the rough human 
sequence working draft. The Science issue in the same month focused on the draft 
sequence produced by the private company Celera Genomics (Venter et al. 2001). These 
analyses revealed that human genome consists of 3.1647 billion base pairs and that the 
number of genes is much smaller than earlier anticipated; approximately 30,000 instead of 
an earlier estimate of 80,000 genes. The number of genes has later been redefined as 
20,000-25,000 (International Human Genome Sequencing Consortium 2004); still the 
accurate number is unknown. The number of human genes is surprisingly low, because 
even a rather unsophisticated nematode worm, C. elegans, has about 20,000 protein 
coding genes (The C. elegans Sequencing Consortium 1998). It is believed that the 
complexity of human and other vertebrates is achieved by finely regulated gene expression 
mechanisms, alternative splicing, and an ever increasing number of identified RNA 
transcripts that do not code for proteins (Claverie 2001, Claverie 2005).  
 
In the human genome, the sizes of genes vary a lot, the average being about 3,000 bp per 
gene, while the largest human gene, dystrophin, contains 2.4 million bp. Less than 2% of 
DNA is within genes that encode for a protein, and repetitive sequences that do not code 
for proteins constitute at least 50% of the human genome. In 2004, the cleaned version of 
the human genome sequence with high accuracy (an error rate estimated to be less than 
1/100,000 nucleotides) and nearly complete coverage was published (International Human 
Genome Sequencing Consortium 2004). The sequence covers approximately 99% of the 
euchromatic genome, and thus several gaps still need to be filled. Most of these gaps are 
associated with segmental duplications, which are difficult to sequence with traditional 
methods. The near completion of the human genome sequence is only the first step, while 
still the exact number of genes, their location, and function remains to be solved. The 
entire sequence of the human genome is publicly available in several internet databases 
such as the Ensemble genome browser (http://www.ensembl.org/Homo 
_sapiens/index.html) and the NCBI sequence database (http://www.ncbi.nlm.nih.gov/). 
REVIEW OF THE LITERATURE 
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1.2 Variation in the Human genome 
DNA sequences of any two human individuals are believed to be 99.9% identical 
(Kruglyak and Nickerson 2001). It has been estimated that more than 90% of genomic 
variability between individuals consists of single nucleotide polymorphisms (SNPs), 
which are by definition variations of a single base pair with a minor allele frequency 
(MAF) of at least 1 % in at least one population. Other well known variations in the 
genome are variable number of tandem repeats (VNTR) that include minisatellites 
(tandemly repeated sequences of several nucleotides) and microsatellites (tandemly 
repeated sequences of 1-6 nucleotides; also called short tandem repeats (STRs) and simple 
sequence repeats (SSRs)), small insertion/deletion polymorphisms, transposable elements 
(e.g. Alu elements), copy number variants (CNVs), and structural alterations (e.g. 
inversions, deletions, and duplications) (Strachan and Read 2004). The common sequence 
variations found in human genome are listed in Table 1. 
 
Table 1. Sequence variations in the human genome. 
Polymorphism Type Size Estimated number in 
the human genome 
Reference 
SNP biallelic 1 bp 11 million Kruglyak and 
Nickerson 2001  
Insertion/deletion biallelic 1-few hundred bp ~250,000 Weber et al. 2002 
Microsatellite multi- 
allelic 
Variable number of 
1-6 bp repeats 
~210,000 (2-3 nt 
repeats) 
Lander et al. 2001, 
Subramanian et al. 
2003 
Minisatellite multi- 
allelic 
Variable number of 
6-few hundred bp 
repeats 
~30,000 (≥6 nt repeats) Naslund et al. 2005 
 
CNV biallelic 300-460 kb on 
average 
~11-12 /when two 
individuals compared) 
Sebat et al. 2004, 
Iafrate et al. 2004 
Polymorphic 
Transposable (Alu) 
elements 
biallelic ~300bp ~1200 Tishkoff and 
Verrelli 2003 
 
1.2.1 Single nucleotide polymorphisms 
Single nucleotide polymorphisms (SNPs), the most simple and common type of variation, 
have an estimated density of one per every 1000 bp along the human genome if two 
individuals are compared. The total density of SNPs among people all over the world is 
obviously much higher. Although SNPs exist both in coding and non-coding regions of 
the genome, they are distributed with unequal spacing (Sachidanandam et al. 2001). Most 
SNPs do not have an effect on cell function, but some are believed, for example, to 
predispose people to disease, or to influence the individual’s response to a drug. This 
depends largely on where a SNP occurs (Syvänen 2001). Non-synonymous (amino acid 
altering) SNPs in coding regions of a gene are of course believed to be important in 
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causing genetic diseases because they may change the structure and function of the 
encoded protein. However, it has recently been realized that also synonymous SNPs 
(silent; coding SNPs that do not alter the amino acid), intergenic SNPs, and SNPs in 
introns and other non-coding regions may be functional. If these variations are located in 
promoters, splice junctions, or 5’ and 3’ untranslated regions, they may alter the structure, 
function, and expression of the gene product by affecting the regulation, splicing, and 
mRNA stability of a gene (Pagani and Baralle 2004, Capon et al. 2004). 
 
Even though there are four nucleotide possibilities in principle, SNPs are usually biallelic. 
This can be explained by the assumption that most of the SNPs have arisen through a 
single mutation event in the history of a population, and the probability that the mutation 
would occur at the same site is low (Stoneking 2001). Approximately two thirds of SNPs 
are transition substitutions between double ring structured purines (nucleotides A and G) 
or between single ring structured pyrimidines (nucleotides T and C), whereas one third of 
SNPs are transversion substitutions between a purine and a pyrimidine nucleotide (Guo 
and Jamison 2005). Coding region SNPs, synonymous or non-synonymous, comprise only 
a minority of all SNPs. It has been hypothesized that the SNP frequency in the sequences 
that are functionally important and therefore under the evolution pressure is much lower 
than in the sequences that are irrelevant for the function (e.g., introns, repetitive 
sequences, and pseudogenes). Therefore it is surprising that there are more SNPs near to 
the transcriptional start sites than in other parts of the genome on average (Guo and 
Jamison 2005). The estimated number of common SNPs, with a minor allele frequency 
(MAF) of more than 5%, is 7 million. In addition, there are a large number of rare SNPs 
(MAF 1-5%) raising the estimated total number of SNPs as high as 11 million. Of the 
common SNPs, approximately 85% are shared between different populations. In other 
words, only 15% of common SNPs are confined to certain population (Kruglyak and 
Nickerson 2001). Genetic drift, population growth, bottlenecks, admixture, and natural 
selection are potential mechanisms that underlie the differences between populations in 
allele frequencies (Ardlie et al. 2002). 
 
1.2.2 Single nucleotide polymorphisms and microsatellites as genetic 
markers  
Basically all genetic variations with an identifiable physical location and pattern of 
inheritance can be used as genetic markers. Therefore even the SNPs that are not 
functional are very important for genetic research. Another commonly used marker is a 
microsatellite, which consists of repeating units of 1-6 nucleotides, the number of 
repetitive units varying highly between individuals. These small repetitive sequences are 
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spread throughout the genome but are more common in the non-coding regions (Toth et al. 
2000, Subramanian et al. 2003). The microsatellites that are used as markers for gene 
mapping purposes consist usually of di-, tri, and –tetra nucleotide repeats. As genetic 
markers, their information content is higher than that of the biallelic SNPs, but SNPs are 
genetically more stable and more abundant than microsatellites (Toth et al. 2000, 
Subramanian et al. 2003). Today, genetic markers can be easily selected from public 
databases. The most current build of the NCBI’s dbSNP database (Build 126; May 18, 
2006; http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi) contains nearly 12 
million SNPs, of which 5.6 million have been validated. Of all the catalogued SNPs, 4.1 
million are located in gene related sequences; however, with the majority of these gene-
related SNPs locating in introns and other non-coding regions. In addition to actual SNPs, 
small biallelic insertion/deletion polymorphisms are also reported in SNP databases, and 
therefore the number of reported SNPs in databases is slightly higher than the current 
estimates. Several genome-wide microsatellite maps, such as the Marshfield map (Broman 
et al. 1998) and the more recent deCODE Genetic map of over 5,000 microsatellites 
(Kong et al. 2002), include information about physical distances as well as genetic 
distances of microsatellite markers, which are determined by measuring the rate of meiotic 
recombinations between the markers. 
 
1.2.3 Large-scale copy number variations 
Only recently it has become evident that large-scale copy number variations (CNVs), also 
called copy number polymorphisms (CNPs), constitute a large proportion of human 
genetic diversity (Sebat et al. 2004; Iafrate et al. 2004). CNVs are defined as repetitive 
sequences, in which a repetitive unit is as large as 100 kb or greater. CNVs are widely 
distributed throughout the genome, also in coding regions, although obvious hot spots do 
exist. The average size of CNVs is estimated to be 300-460 kb and there are, on average, 
11-12.4 CNVs between two individuals (Sebat et al. 2004, Iafrate et al. 2004). However, 
these numbers are probably underestimates due to the small number of individuals 
assessed in these studies and the limited resolution of detection methods. It is still unclear 
what other genomic features, in addition to segmental duplications, enhance the 
occurrence of CNVs (Freeman et al. 2006). These CNVs are likely to complicate the 
genotyping of smaller variations such as SNPs and microsatellites. 
 
1.3 HapMap project 
The Human Genome Project identified 1.4 million SNPs in the human genome. The 
international HapMap project continued this work, aiming at identifying all common 
variation between 269 individuals in different populations originating from Africa, Asia, 
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and Europe. The European sample (abbreviation CEU) consists of 90 individuals (30 
parent-offspring trios) from a U.S. population with Northern and Western European 
ancestry collected by the Center d´Etude du Polymorphisme Humain (CEPH). In addition, 
the African population sample (abbreviation YRI) from the Yoruban people of Ibadan, 
Nigeria, includes 30 parent-offspring trios. The third population sample from Tokyo, 
Japan (abbreviation JPT), consists of 44 unrelated individuals and the fourth population 
sample from Beijing, China (abbreviation CHB), consist of 45 unrelated individuals. It is 
hoped that with these samples it would be possible to identify most of the common 
variation in different populations all over the world. In the phase I of the HapMap project, 
1.01 million SNPs (at least one common SNP every 5 kb across the genome) passed the 
quality control measures. The number of identified non-synonymous coding SNPs was 
11,500. In the phase II, an additional 4.6 million SNPs were genotyped 
(http://www.hapmap.org; The International HapMap Consortium 2005). 
 
1.3.1 Linkage disequilibrium structure of the human genome 
The ultimate goal of the HapMap was to provide a catalogue of common human variation 
between individuals, which then could be used to create a linkage disequilibrium (LD) 
map of the human genome. Alleles that exist close to each other in a chromosome tend to 
be inherited together more often than would be expected by chance. This phenomenon is 
called linkage. Linkage disequilibrium (LD) means that even on the population level, 
certain alleles tend to co-occur together in a chromosome more often than expected based 
on their overall population frequencies. Polymorphisms that are in LD with each other 
have not been separated by recombinations or new mutations and thus share a common 
ancestry (Reich et al. 2001; Gabriel et al. 2002). There are several measures to describe 
the strength of LD, of which the most widely used are D’ and r2. In both of these measures 
value 0 implies that the two tested markers are independent, whereas value 1 means that 
the markers have not been separated by recombination. D’ equals 1 if the rarer allele 
occurs always with one of the two alleles at the other marker, whereas r2 equals 1 only if 
the allele frequencies are identical (Zondervan and Cardon 2004).  
 
It has become apparent that recombination does not occur evenly along the human 
genome. Instead, there are loci in which recombination occurs more often than in the 
genome on average (recombination hot spots), and areas in which recombination is a rare 
event (recombination cold spots). Partly because of this phenomenon, the human genome 
consists of LD blocks, also called haplotype blocks. In these block-like structures only few 
haplotypes (a combination of neighboring markers along a single chromosome) can 
explain all of the common variation in that region, although the theoretical number of SNP 
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combinations, if they were random, would be much higher (Daly et al. 2001, Reich et al. 
2001, Patil et al. 2001, Gabriel et al. 2002). However, it has been suggested that 
recombination hot spots are not prerequisite for the formation of haplotype blocks; block-
like structure might arise simply by the interplay of randomly distributed recombination, 
population history, and mutations (Wang et al. 2002).  
 
The older age of African populations compared to populations of non-African origin is 
reflected on the sizes of haplotype blocks; the average block size is estimated to be 11 kb 
in African and African-American individuals, whereas it is estimated to be 22 kb in 
European individuals, although the sizes of blocks differ a lot in different loci (Gabriel et 
al. 2002). There are several different algorithms to measure the block boundaries, and thus 
the definition of the haplotype block is still quite ambiguous (Gabriel et al. 2002, Wang et 
al. 2002). Haploview software (Barrett et al. 2005), which is commonly used to define LD 
structure and haplotype block boundaries from the genotype data, offers several different 
algorithms for block definition from which the user can choose (Barret et al. 2005), and 
they give quite different results. Irrespective of the algorithm used to define the block 
boundaries, a typical feature of the haplotype block is that only three to five common 
haplotypes cover over 90% of all haplotypes observed (Gabriel et al. 2002). 
 
The LD maps created by the HapMap can be used to select haplotype tagging SNPs 
(tagSNPs), which capture the variation in the block without genotyping all the 
polymorphic markers. This helps genetic association studies tremendously by reducing the 
number of needed markers. Although widely accepted, the HapMap has also been 
criticized. Terwilliger and Hiekkalinna (2006) pointed out in their study that allelic 
heterogeneity across multiple haplotypes may lead to false negative associations if only 
tagSNPs are used. Other concerns have been the low number of genotyped individuals in 
the HapMap project, their usefulness in other populations, and bias towards common 
variation (Montpetit et al. 2006). It is true that the only way to capture all of the variation 
between individuals is to sequence the whole genome, but this is still out of reach with 
today’s technologies, and would bring new statistical concerns including an even larger 
multiple testing problem. Meanwhile, the information produced by the HapMap project is 
a great shortcut to cover most of the common variation between individuals.  
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2 IDENTIFICATION OF SUSCEPTIBILITY GENES FOR COMPLEX DISEASES 
 
2.1 Complex diseases 
Identification of genes behind monogenic diseases obeying Mendelian inheritance has 
been very successful in the recent decade all over the world (Kerem et al. 1989, Riordan et 
al. 1989, Huntington's Disease Collaborative Research Group 1993), also in Finland 
(Hästbacka et al. 1994, Höglund et al. 1996, Vesa et al. 1995). Therefore, expectations for 
disease susceptibility gene identification for common multifactorial diseases have been 
high. Unfortunately this task has proven difficult (Altmüller et al. 2001). Multifactorial 
diseases are complex; not only a single gene but several genetic factors, in addition to 
environmental factors, play a role in the predisposition to these diseases. In addition, gene-
gene and gene-environment interactions are believed to have a significant influence on the 
etiology of complex diseases (Page et al. 2003, Chakravarti and Little 2003, Hunter 2005, 
Wang et al. 2005).  
 
The common disease - common variant hypothesis (Risch and Merikangas 1996, Lander 
1996, Reich and Lander 2001) suggests that common polymorphisms underlie common 
diseases such as type 2 diabetes, asthma, and cardiovascular diseases, whereas rare 
variants cause only very rare diseases. The opposing hypothesis suggests that multiple rare 
polymorphisms, distinct in different individuals, predispose to common diseases (Cargill 
et al. 1999, Chakravarti 1999, Smith and Lusis 2002). The underlying allelic structure is 
probably somewhere between these two hypotheses (Wang et al. 2005). However, 
common variants may be more valuable for diagnostic and intervention purposes, because 
a common variant represents a larger population attributable risk than a rare one. In 
addition, very large sample sizes are required to obtain statistically meaningful results if 
very rare alleles are being evaluated (Hinds et al. 2005). Despite an obvious genetic 
component for the most common diseases, the number of reproducible associations has 
been remarkably small in relation to the resources used for this research. This is 
considered to be due to several different factors including genetic heterogeneity (meaning 
the production of identical or similar phenotypes by different genetic mechanisms), 
reduced penetrance (indicating the likelihood that a given gene variant will actually result 
in disease), smaller impact of an individual gene, differences between populations, 
contribution of environmental factors, too small sample sizes, etc. (Risch and Merikangas 
1996, Hirschhorn and Daly 2005, Wang et al. 2005).  
 
However, the few successes have been encouraging in showing that the identification of 
susceptibility genes for common multifactorial diseases may be a difficult but not an 
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impossible task. These successful findings include the positional cloning of 
Apolipoprotein E (APOE) as a susceptibility gene for Alzheimer’s disease (Strittmatter et 
al. 1993), Crohn’s disease susceptibility gene NOD2/CARD15 (Hugot et al. 2001, Rioux et 
al. 2001), a new G protein coupled receptor gene (GPRA or GPR154) (Laitinen et al. 
2004) and a disintegrin and metalloprotease 33 gene (ADAM33) (Van Eerdewegh et al. 
2002) as asthma susceptibility genes, and very recently a transcription factor 7-like 2 
(TCF7L2) gene as a type 2 diabetes susceptibility gene (Grant et al. 2006). These findings 
have all been replicated in several different populations (Tsuda et al. 1994, Mirza et al. 
2003, Melén et al. 2005, Kormann et al. 2005, Feng et al. 2006, Howard et al. 2003, 
Werner et al. 2004, Groves et al. 2006, Saxena et al. 2006, Scott et al. 2006), confirming 
that the above mentioned genes most probably play important roles in the etiologies of 
these complex diseases. Also a few candidate-gene approaches have been fruitful, one of 
the most convincing associations being the peroxisome proliferator-activated receptor 
gamma (PPARG) Pro12Ala polymorphism with type 2 diabetes (Altshuler et al. 2000, 
Stumvoll and Haring 2002). 
 
2.2 Disease gene mapping approaches 
There are two main approaches that are used in the mapping of genes for inherited 
diseases. Linkage analysis utilizes affected and unaffected individuals in families to search 
for co-segregation of disease locus and marker alleles, whereas the simplest form of 
association analysis compares the frequency of marker alleles between affected and 
unaffected unrelated individuals. These two approaches are described briefly in the next 
two sections. A shift of focus from monogenic diseases towards common complex 
diseases during the last decade has increased the number of conducted association studies 
compared to the number of linkage studies (Botstein and Risch 2003). This is due to the 
fact that family based linkage studies have not been very successful in the identification of 
susceptibility loci for complex diseases (Risch and Merikangas 1996, Altmüller et al. 
2001). The difficulty in collecting a sufficiently large number of family pedigrees is 
perhaps one explanation for these failures, as the odds ratio (OR) estimates for the 
previously identified genes suggest that most studies have been under-powered to detect 
such weak effects. Family based analysis can also be problematic for complex traits due to 
genetic heterogeneity. A fairly common opinion is that an association study would offer 
higher resolution and greater power than a linkage study to identify low-penetrance 
variants (Risch and Merikangas 1996, Ardlie et al. 2002, Freimer and Sabatti 2004). An 
association study is also more appropriate, if interactions between genetic and 
environmental factors are aimed to be identified (Freimer and Sabatti 2004).  
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Two additional approaches called Admixture Mapping (Smith and O’Brien 2005, 
McKeigue 2005) and Subpopulation Difference Scanning (Salmela et al. 2006) have 
recently been proposed, but remain largely untested. Admixture Mapping is an alternative 
approach for whole-genome scan and utilizes populations of mixed ancestry in the 
localization of disease-causing variants. In this approach, the disease of interest and 
markers to be genotyped need to exhibit different frequencies across the two ancestral 
populations. For this whole-genome haplotype-based mapping, only 2,000-3,000 markers 
are required, providing a significant economic advantage compared to genome-wide 
association studies (Smith and O’Brien 2005, McKeigue 2005). In Subpopulation 
Difference Scanning, unrelated individuals from highly related subpopulations 
representing different disease incidence are studied. The genetic regions, defined by the 
markers that do not represent allele or haplotype frequency differences between the 
subpopulations, can be excluded from explaining the disease incidence difference. The 
approach simplifies the sampling process by using randomly sampled individuals from 
certain subpopulations instead of cases and controls (Salmela et al. 2006). 
 
2.2.1 Linkage study 
Disease gene mapping is traditionally started with a genome-wide linkage analysis, in 
which no prior assumptions of the disease loci are made. The aim is to locate a 
chromosomal region that co-segregates with the trait of interest in one or more families. 
This is done by genotyping evenly spaced and highly variable genetic markers, usually 
microsatellites, throughout the genome. Approximately 400 microsatellite markers are 
generally adequate for an initial scan, because closely related individuals share long 
regions of genome that is inherited from the same ancestor. These genotypes together with 
the pedigree information are used in computational analyses to localize chromosomal 
segments that are hoped to contain the disease predisposing gene. Additional markers are 
then used to fine-map, i.e., narrow down the linked region. Linkage is a tendency of loci to 
be inherited together because they are not separated by recombinations during meiosis due 
to their close proximity to each other. However, because there are a limited number of 
recombination events within a family, the linked region cannot usually be narrowed down 
below several megabases (Ewens and Spielman 2001, Carlson et al. 2004). 
 
Linkage analysis can be either parametric or non-parametric, depending whether the mode 
of disease inheritance is described or not in the model. In the studies of complex diseases 
that do not follow the Mendelian pattern of inheritance, non-parametric linkage is usually 
preferred (Kong and Cox 1997). As mentioned earlier, linkage analysis has been 
successful in the identification of rare, severe, and high risk mutations causing monogenic 
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diseases. To detect susceptibility alleles that confer only modest disease risks, association 
analysis is believed to be much more powerful (Risch and Merikangas 1996, Ardlie et al. 
2002, Freimer and Sabatti 2004). 
 
2.2.2 Association study  
Association analysis in its simplest form compares the frequency of marker alleles 
between affected and unaffected unrelated individuals. It is typically conducted by 
genotyping genetic markers in the chromosomal region that has been identified by earlier 
genome-wide linkage analysis, or in potential candidate genes based on their biological 
function. An allele that occurs at a significantly higher (or lower) frequency among 
affected individuals is considered to be associated with the disease (or to be protective) 
(Ewens and Spielman 2001). This is usually tested by using a chi-square test. However, 
because of the LD structure in the genome, the associating marker can be in LD with the 
actual causative variant, and thus association does not imply causality. Although this is a 
disadvantage in direct association analysis, in which the variant itself is thought to 
predispose to disease, this phenomenon has been utilized in indirect association studies, 
aimed at narrowing down the locus in which the susceptibility gene resides. The resolution 
of this LD based mapping is much higher than in traditional linkage analysis. Association 
analysis can also be performed for phenotypes that are quantitative. Students’ t-test  or 
analysis of variance (ANOVA) are standard procedures to perform this kind of analysis, in 
which a quantitative phenotype is used as a dependent variable and genotypes as 
independent variables (reviewed in Nielsen and Zaykin 2001).  
 
Population stratification, which can lead to false positive associations between a marker 
and phenotype, is a recognized problem in association studies. If the allele frequency and 
disease frequency differ between subpopulations, spurious associations are very likely to 
occur (Pritchard et al. 2000). One solution for this problem is the use of founder 
populations, populations that have been derived fairly recently from a limited number of 
individuals (Hirschhorn and Daly 2005, Laitinen et al. 2004). The use of these genetic 
isolates also reduces the genetic diversity, and is thereby advantageous in genetic linkage 
and association studies by simplifying the genetic background of a given trait (Varilo and 
Peltonen 2004). The population from Finland, and its subpopulations such as Kainuu, has 
been successfully utilized in the studies of complex diseases (Laitinen et al. 2004). 
Another commonly used solution for the population stratification problem is the 
transmission/disequilibrium test (TDT), in which the genotypes of parents of affected 
individuals are used (Spielman et al. 1993). However, it is much more laborious and time 
consuming to collect DNA from parents of affected individuals than from unrelated 
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individuals. Therefore traditional case-control studies with unrelated individuals are still 
needed and largely used.  
 
The selection bias, in which cases and controls are not fully comparable, can also be 
avoided by using a prospective cohort study. In this study design, individuals have been 
selected before disease onset and are followed up until the occurrence of a specific 
outcome. The prospective cohort study is invaluable because it allows risk estimates to be 
made at a population level and environmental factors to be monitored. However, long 
duration and large samples sizes have restricted the use of this obviously advantageous 
study design (Cardon and Bell 2001, Manolio et al. 2006). Regardless of the used study 
design and sample size, the association findings should be replicated in an independent 
population. 
  
2.2.2.1 Haplotypes instead of individual SNPs 
In today’s association analyses, the use of haplotypes instead of individual SNPs is 
preferred (Akey et al. 2001, Morris and Kaplan 2002, Zhao et al. 2003). Since haplotypes 
are composed of combinations of polymorphisms, they contain more information than 
individual unorganized SNPs, and therefore may provide more statistical power. The use 
of haplotypes also enables the examination of allelic variation at a larger scale, such as the 
level of a whole gene, instead of a single polymorphism that may well not be the 
functional one, even if it would have been associated with the trait of interest. It has also 
been suggested that unknown rare gene variants occur in a single haplotype, because rare 
variants have most probably arisen relatively recently and recombinations have had less 
time to disrupt the haplotype. Consequently, these rare variants could be detected with the 
haplotype approach (Akey et al. 2001, Hirschhorn and Daly 2005). Probably the most 
important reason to use haplotypes is the decreased number of SNPs required to obtain the 
comprehensive information, because haplotype tagging SNPs (tagSNP) can serve as 
proxies for many other SNPs if the LD structure of the given locus is known (Daly et al. 
2001, Johnson et al. 2001, Gabriel et al. 2002, Hirschhorn and Daly 2005). 
 
Although molecular methods to assign haplotypes do exist (Yan et al. 2000, Douglas et al. 
2001), they are still too expensive and time-consuming for large-scale studies. Therefore, 
haplotypes are commonly inferred statistically both from pedigree (Zhang and Zhao 2006) 
and population-based genotype data (Adkins 2004). Studies comparing statistically 
inferred haplotypes with molecularly determined haplotypes have shown that most 
algorithms are accurate in haplotype inference (Adkins 2004). 
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2.2.2.2 Genome-wide association studies 
Already in 1996, Risch and Merikangas (Risch and Merikangas 1996) introduced the 
concept of a genome-wide association (GWA) study using SNPs. GWA does not rely on 
having predicted the correct genes or gene variants, and therefore, in theory, has a better 
chance to identify the disease predisposing genes. Thus far, association studies comprising 
the whole human genome have not been realistic, mainly because of the large amount of 
genotyping required. However, the advent of DNA microarray technology during the 
recent years has brought about a massive increase in high-throughput genotyping capacity. 
As the HapMap project has simultaneously created knowledge about the haplotype 
structure of human genome, the amount of genotyping required to obtain the same 
information has been reduced. Therefore, comprehensive studies identifying most of the 
common variation in the human genome have become feasible (Wang et al. 2005, 
Hirschhorn and Daly 2005, Palmer and Cardon 2005). Several commercial panels are 
already available to conduct a GWA study, the marker sets varying from 100,000 to 
550,000 SNPs (Barrett and Cardon 2006). Some of the commercial sets are focused on 
potential functional variants, whereas many panels aim to cover most of the common 
variation irrespective whether they are located in genes or not (see Table 2). The 
commercial panels that are available for GWA at the moment are listed in Table 2. Pe'er 
and co-workers estimated in their recent study that both a randomly selected set of 
~500,000 SNPs (Affymetrix GeneChip 100K) and ~300,000 tagSNPs (Illumina 
HumanHap300) would capture 80-86% of common alleles (MAF ≥ 5%) in the CEU 
population (Pe'er et al. 2006). 
 
Table 2. Examples of currently available marker panels to conduct genome-wide 
association studies. 
GWA panel Number of 
SNPs 
SNP selection 
Affymetrix GeneChip 100K1 116,204 Randomly selected SNPs across the genome 
Affymetrix GeneChip 500K2 500,568 Randomly selected SNPs across the genome 
Illumina Human-13 ~109,000 Gene-centric: SNPs in or within 10kb of exons, in 
known transcripts, and in highly conserved regions 
Illumina HumanHap3004 ~317,000 HapMap tagSNPs based on LD in Caucasian 
population 
Illumina HumanHap5505 ~555,000 tagSNPs based on LD in all HapMap populations, plus 
SNPs in mitochondria and in known CNVs 
1http://www.affymetrix.com/support/technical/byproduct.affx?product=100k 
2http://www.affymetrix.com/products/arrays/specific/500k.affx 
3http://www.illumina.com/Products/ArraysReagents/wgghuman1.ilmn 
4http://www.illumina.com/Products/ArraysReagents/wgghumanhap300.ilmn 
5http://www.illumina.com/Products/ArraysReagents/wgghumanhap550.ilmn 
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The statistical analysis of the results of a GWA study is still somewhat problematic, and 
there is no clear consensus how these problems should be overcome. The number of 
conducted tests is large, and if corrected for multiple testing using traditional ways such as 
Bonferroni correction (Bland and Altman 1995), there is a great possibility that all true 
associations would be missed with currently available study sample sizes. Hirschhorn and 
Daly proposed in their recent paper (Hirschhorn and Daly 2005) that a so-called multi-
stage approach would address this problem by minimizing the number of genotypes 
required, without sacrificing power. The first stage of genotyping would be performed 
with a full marker set covering the whole genome, but only in a fraction of samples. SNPs 
for further analyses would be selected based on the strength of association with 
phenotypes of interest, with a selection threshold liberal enough to have power to also 
detect loci that contribute only modestly to the phenotypic variance. Obviously a large 
number of false-positives will pass this threshold, but the number will decrease during the 
next stages of genotyping. In the second stage a larger, independent set of samples is 
genotyped only with markers that passed the p-value threshold. A more stringent criterion 
is used this time for positive associations. A third stage continues with the rest of the 
samples by using only markers that passed the p-value threshold in the preceding two 
stages. These thresholds will be defined by permutation testing so that approximately 5% 
of the analyses will give a positive association (including false and true associations) 
(Hirschhorn and Daly 2005).  
 
There is an increasing number of published studies showing initial results of these GWA 
studies. Ozaki and co-workers identified a candidate locus on chromosome 6p21 
associated with susceptibility to myocardial infarction by using 92,788 gene-based SNPs 
(Ozaki et al. 2002). Klein and colleagues used Affymetrix 100K GeneChip and found an 
association between age-related macular degeneration and a common variant in the 
complement factor H gene (Klein et al. 2005). However, the coverage of these SNP sets is 
not as good as in the currently available marker panels (see Table 2). It is anticipated that 
published GWA studies with the state-of-the-art coverage will soon emerge.  
 
 
3 SNP GENOTYPING TECHNIQUES 
 
3.1 Evolution of SNP genotyping techniques 
Most of the modern SNP genotyping technologies have been developed in the new 
millennium. However, the basic concept of several techniques lies in much older 
inventions. Southern hybridization (Southern 1975), which is based on the hybridization 
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of labeled oligonucleotide probes with the homologous restriction enzyme fragmented and 
gel separated genome, enabled the earliest mutation analyses. In 1978, using the Southern 
technique, researchers found a restriction fragment length polymorphism (RFLP) that 
changed the digestion site for a specific restriction enzyme in the β-globin gene. This 
sequence variation was found to cause β-thalassemia and sickle cell anemia (Kan and 
Dozy 1978). The variant allele was frequently associated with the sickle hemoglobin 
mutation, and it was suggested that this RFLP could be useful in prenatal diagnostics. A 
few years later a RFLP near the human insulin gene was found to be associated with non-
insulin dependent diabetes (Owerbach and Nerup 1982). RFLPs, which include also SNPs, 
have since been commonly used as markers for disease gene mapping purposes. 
 
Another early SNP genotyping method was based on hybridization with allele-specific 
oligonucleotide (ASO) probes, and was used for the first time in 1983 to directly 
determine the different alleles in β-globin gene (Conner et al. 1983, Orkin et al. 1983, 
Pirastu et al. 1983). This approach utilized the specificity of hybridization; under 
appropriate conditions a single base mismatch is enough to destabilize the hybridization. 
This phenomenon enables the assessment of the genotype by using two probes, one 
specific for the wild-type allele and another for the variant allele.  
 
Although these hybridization methods are still widely used, it was the invention of the 
polymerase chain reaction (PCR) (Saiki et al. 1985, Mullis et al. 1986, Mullis and Faloona 
1987) that really revolutionized the field of variation analysis. PCR, which multiplicates 
the specific target DNA-fragment in the DNA polymerase enzyme catalyzed reaction, 
reduces the complexity of the genome tremendously and enables the further reactions to 
assess the sequence variations sensitively and specifically at the level of even one bp. 
Even though the dideoxy sequencing method had been developed much earlier by Sanger 
and co-workers (Sanger et al. 1977), mutation detection and genotyping with direct 
sequencing were feasible only after the invention of PCR (Wong et al. 1987). In addition, 
hybridization with allele-specific oligonucleotide probes became more sensitive and 
specific, and probe hybridization was much more simple in the form of “dot blot” (Saiki et 
al. 1986). Soon after the invention of PCR, the analysis of restriction site variation (Saiki 
et al. 1985, Kogan et al. 1987) and ligase mediated genotyping (Landegren et al. 1988) 
also became more specific and practical. Due to its simplicity, sensitivity, specificity, and 
reliability, PCR is actually even today an integral part of the majority of genotyping 
techniques. 
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In 1990, Syvänen and co-workers introduced the primer extension technique, also called 
minisequencing (Syvänen et al. 1990). In primer extension, the DNA polymerase enzyme 
catalyzes the elongation of a primer, which is annealed immediately 5’ to the SNP site by 
incorporating specific nucleotides that are complementary to the template DNA sequence. 
Different applications utilize either dideoxynucleoside triphosphates (ddNTPs), which 
terminate the elongation (single base extension; SBE), or deoxynucleoside triphosphates 
(dNTPs), which enable the primer to be extended by more than a single nucleotide. In 
allele-specific primer extension (ASPE), the SNP-specific primer is either extended or not 
depending on the allele (Tost and Gut 2005). In the original approach by Syvänen and co-
workers, a fragment containing the SNP of interest is first PCR amplified by using one 5’ 
biotinylated primer. Biotinylated DNA fragment is kept as single stranded and purified 
from excess PCR primers and dNTPs, by immobilizing it to streptavidin matrix. This is 
based on the interaction between glycoprotein avidin and its ligand biotin. The SNP allele 
is then identified from the immobilized amplicon by using a primer that anneals 
immediately upstream to the SNP site and extends it by a single labeled ddNTP 
complementary to the template (Syvänen et al. 1990). This basic idea, with different 
detection and purification approaches, has been utilized in numerous modern techniques, 
including SNaPshot (Applied Biosystems) (Makridakis and Reichardt 2001), MassArray 
MALDI-TOF (Sequenom) (Nakai et al. 2002, Storm et al. 2003), and SNP stream (Orchid 
Biosciences) (Bell et al. 2002). 
 
Today there are over 100 different approaches to genotype SNPs. The majority of them 
still require the target amplification by PCR to reach the required specificity and 
sensitivity. The subsequent steps, irrespective of approach, can be divided into allelic 
discrimination, detection, and allele scoring (see Figure 1). In addition, it is important to 
distinguish between assay formats, which can be basically divided into two categories: 
reactions that occur in solution are referred to as homogenous reactions, and reactions that 
occur on a glass slide, chip (microarrays) or microbead, are referred to as solid-support 
reactions (Syvänen 2001, Kwok 2001, Tsuchihashi and Dracopoli 2002, Chen and 
Sullivan 2003, Twyman and Primrose 2003).  
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Figure 1. Different steps and alternative approaches in SNP genotyping. 
 
 The most commonly used approaches for allelic discrimination include allele-specific 
hybridization, primer extension, oligonucleotide ligation, and enzymatic cleavage. This is 
followed by the detection of allele discrimination products, for which a variety of different 
techniques are also available. Detection based on luminescence, fluorescence, 
fluorescence resonance energy transfer (FRET), fluorescence polarization (FP), and 
absorbance utilize the light emitted by the products. Change in the electrical property and 
mass spectrometry, which discriminates the alleles based on the mass of the products, are 
also widely used detection techniques (Syvänen 2001, Chen and Sullivan 2003, Sobrino et 
al. 2005). The automatic allele scoring is a basic prerequisite for today’s genotyping 
because of the high-throughput requirements. Figure 2 illustrates the most commonly used 
biochemical reaction principles for allelic discrimination. 
 
Allele scoring
Allelic discrimination
Allele specific oligonucleotide hybridization
Primer extension
Oligonucleotide ligation
Enzymatic cleavage
Detection
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Fluorescence Resonance Energy Transfer (FRET)
Fluorescence polarization (FP)
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Target amplification
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Figure 2. Biochemical reaction principles for allelic discrimination in widely used 
SNP genotyping techniques. a) Hybridization with allele-specific oligonucleotide 
probes; b) Allele-specific primer extension (ASPE); c) Single base extension (SBE) 
with fluorescence detection; d) Allele-specific ligation; e) Restriction fragment length 
polymorphism (RFLP) (modified from Syvänen 2001). 
 
The increased throughput in genotyping can be obtained by multiplexing the PCR assays, 
which also decreases the genotyping costs. Multiplexing capability is thus an important 
aspect when evaluating different genotyping platforms. However, multiplexing of more 
than 20 amplicons in the PCR reaction has proved to be very difficult (Syvänen 2005). A 
big step towards a higher throughput in SNP genotyping was the implementation of 
oligonucleotide microarrays (Chee et al. 1996, Yershov et al. 1996, Shumaker et al. 1996, 
Pastinen et al. 1997), which offer a solid-phase supporter for genotyping. Hundreds of 
thousands of predefined sequences can be arrayed in a small area, by which the high 
throughput can be achieved. The typical feature of the microarray based genotyping 
platform is that a large number of SNPs can be genotyped from one or a small number of 
samples at a time. Various allele discrimination methods can be used on microarrays, the 
most popular ones being primer extension (Shumaker et al. 1996, Pastinen et al. 1997) and 
allele specific hybridization (Chee et al. 1996, Yershov et al. 1996). The detection is based 
on light emitted from specific spots on the chip. The largest company in the microarray 
field is Affymetrix, which offers DNA chips for gene-expression studies as well as for 
SNP genotyping with various sets of SNPs, including genome-wide association studies as 
discussed earlier. 
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3.2 Modern methods and high-throughput genotyping 
High-throughput genotyping technologies have been developed very rapidly during the 
past few years, and similar development is expected to continue. There are several high-
throughput SNP genotyping techniques available today, with the capacity of several 
million genotypes per day. At present, there are at least two technologies that seem to be 
able to fulfill the needs of genome-wide association studies: genome-wide microarrays by 
Affymetrix and Illumina. However, smaller scale genotyping with the possibility to select 
the custom SNPs is still required; therefore medium-throughput methods are still valid. 
Table 3 summarizes the critical features of some of the widely used medium- and high-
throughput techniques. The reaction principles are explained in more detail in the 
following sections. Since numerous other SNP genotyping techniques exist, this example 
aims to represent only some of the commonly used techniques that utilize various allele 
discrimination and detection approaches. 
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Table 3. A summary of popular SNP genotyping techniques (Syvänen 2001, Pati et al. 
2004, Hirschhorn and Daly 2005, Syvänen 2005, and manufacturers’ protocols).  
Method Method of allele 
discrimination 
and detection 
Strength Weakness Number of assays 
and samples 
detected 
simultaneously 
SNapShot 
(Applied 
Biosystems) 
SBE; 
fluorescence  
Compatible with 
capillary- and gel 
electrophoresis 
sequencers 
Extensive 
purification steps 
10-plex assays, 96 
samples 
MassArray 
MALDI-TOF 
(Sequenom) 
Primer 
extension; mass 
spectrometry 
No labeling, 
relatively high 
multiplexing 
High instrument 
cost, long 
protocol 
12-plex assays, 384 
samples 
(MassEXTEND); 
29-plex assays, 384 
samples (iPLEX) 
Pyrosequencing 
(Pyro-
sequencing AB) 
Sequencing-by-
synthesis; 
luminometric 
assay 
Gives a short 
sequence surrounding 
the SNP, real-time 
scoring 
Expensive, long 
prorocol, low 
multiplexing 
level 
1 SNP, 96 samples  
TaqMan 
(Applied 
Biosystems) 
ASOH and 
cleavage; FRET 
during real-time 
PCR 
Closed tube assay, 
simple workflow, 
large selection of 
ready-to-order assays 
Expensive 
fluorescent 
probes, low 
multiplexing 
level 
1 SNP, 96 or 384 
samples 
Invader assay 
(Third Wave 
Technologies) 
Invasive 
cleavage; FRET, 
FP, or mass 
spectrometry 
PCR avoided, 
flexible, wide range 
of potential 
applications 
Requires large 
amount of DNA, 
low multiplexing 
level 
1 SNP, 384 
samples 
GeneChip 
100K/500K  
(Affymetrix) 
Universal PCR, 
ASOH; 
fluorescence 
Universal PCR, 
high throughput 
No 
customization, 
high overall cost 
~100,000/ 
~500,000 SNPs, 1 
sample 
GoldenGate 
(Illumina) 
ASOH, universal 
PCR; 
fluorescence 
Universal PCR, 
Custom SNPs 
although high 
throughput 
High instrument 
cost 
1,536 SNPs, 96 
samples 
Infinium 
(Illumina) 
Whole genome 
amplification; 
ASPE (Infinium 
I), SBE 
(Infinium II); 
fluorescence 
PCR avoided, 
high throughput 
No 
customization, 
high overall cost 
~300,000/ 
~500,000 SNPs, 1 
sample 
 
3.2.1 Commercially available widely used SNP genotyping techniques 
3.2.1.1 SNaPshot 
The SNaPshot method from Applied Biosystems is based on single base extension (SBE) 
after PCR amplification; the allelic discrimination is based on differentially labeled 
ddNTPs, which terminate the extension reaction. In order to be able to detect the 
multiplexed reactions in the capillary- or gel electrophoresis-separation, the extension 
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primers are designed to include neutral tail sequences of variable lengths so that only one 
product will be seen within a size range (Makridakis and Reichardt 2001). 
 
3.2.1.2 MassArray MALDI-TOF 
Sequenom’s MassArray is also based on primer extension after the target amplification by 
PCR. In the first MassArray chemistry, MassEXTEND, the primer that anneals upstream 
of the SNP site is extended depending on the genotype either by one ddNTP, which 
terminates the extension reaction, or by dNTPs until the sequence is complementary to the 
terminating ddNTP (Nakai et al. 2002, Storm et al. 2003). In iPLEX, the more recent 
MassArray assay, all reactions are terminated after a single-base extension (SBE). The 
required mass difference between alleles is obtained by incorporating mass-modified 
ddNTPs. In both reactions allele discrimination is based on the mass of the extended 
products, which is detected using the Matrix-assisted laser desorption/ionization–Time-of-
flight (MALDI-TOF) mass spectrometry. The extension products are spotted onto a chip, 
containing a specific matrix that aids in the desorption and ionization of the DNA. The 
ionization of the DNA molecules is triggered with a laser beam, and the time taken to 
reach the detector in an electric field is based upon the mass of the extended 
oligonucleotide (Nakai et al. 2002, Storm et al. 2003).  
 
3.2.1.3 Pyrosequencing 
Pyrosequencing is a real-time sequencing method that creates a sequence of 20-30 bp by 
using an enzyme cascade to produce light whenever an added dNTP is complementary to 
the template DNA strand. Nucleotides are added in sequence defined order, and when 
nucleotides form a base-pair, pyrophosphate is released, which is then converted to ATP 
by ATP sulfurylase. Luciferase then uses the ATP to generate detectable light, which is 
utilized to deduce the genotype. Apyrase enzyme is used to degrade unincorporated 
nucleotides (Alderborn et al. 2000). 
 
3.2.1.4 TaqMan 5’ exonuclease assay 
The TaqMan® assay is based on allele-specific oligonucleotide hybridization; one probe, 
which is complementary to the wild-type allele and another probe, which is 
complementary to the variant allele, both with different fluorescent dyes attached to the 5’ 
end and a quencher molecule attached to the 3’ end, are included in the real-time PCR 
assay. These probes are hybridized to the template during the annealing step. During the 
extension step, PCR primers are extended, resulting in either the cleavage of the perfectly 
matching probe by a 5’ nuclease activity of the Taq polymerase or the displacement of the 
mismatch probe without fragmentation. If the quencher is close to the fluorescent dye (i.e., 
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in the same probe), it quenches the fluorescence by fluorescence resonance energy transfer 
(FRET), but if the fluorescent dye is cleaved, the fluorescence of the reporter dye 
increases. The genotype can be determined by measuring the signal intensities of the two 
different dyes (Holland et al. 1991, Livak et al. 1995). 
 
3.2.2 PCR free genotyping techniques 
Although PCR is normally required for specificity and sensitivity, it limits the throughput 
of assays, which is a significant disadvantage. Certain ligation and invasive cleavage 
based methods utilize two recognition events, and thereby obtain the required specificity 
without PCR. The sensitivity is achieved by amplifying signals enzymatically. However, 
PCR free genotyping techniques typically require a higher amount of DNA than 
techniques that utilize the PCR amplification. This can in some cases be avoided by using 
the whole-genome-amplification procedure before actual genotyping (Lovmar et al. 2003). 
The Invader assay from Third Wave Technologies, which is based on invasive cleavage, 
Rolling Circle Amplification (RCA), which is based on ligation, and Illumina’s Infinium 
assays are examples of PCR-free genotyping. 
 
3.2.2.1 Invader assay 
In the Invader assay (Third Wave Technologies) (Lyamichev et al. 1999), two 
oligonucleotides, “Invader oligonucleotide” and “probe”, are annealed to the template 
DNA with an overlap of one nucleotide (the SNP site). Flap endonuclease recognizes the 
three dimensional structure, if the two oligonucleotides are perfectly hybridized to the 
target DNA, and cleaves the 5’ arm (called flap) of the probe. In the case of a mismatch, 
flap endonuclease does not recognize the structure. In the case of perfect match, the 
released 5’ flap anneals to the signal probe and initiates the second cleavage reaction. 
Multiple cleaved products are produced per one DNA molecule, and together with the 
secondary cleavage reaction, the signal is amplified exponentially. Therefore, the method 
is sensitive enough without a prior PCR reaction. Different detection methods can be used 
with the Invader assay, including FRET, FP, and mass spectrometry (reviewed in Olivier 
2005). 
  
3.2.2.2 Rolling Circle Amplification 
Another PCR-free genotyping method is based on the ligase-mediated allelic 
discrimination and signal amplification by Rolling Circle Amplification (RCA) (Lizardi et 
al. 1998). The traditional oligonucleotide ligation assay is based on the ability of DNA 
ligase to covalently join two oligonucleotides that are hybridized immediately adjacent to 
each other on a complementary target DNA. This occurs if nucleotides at the junction are 
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correctly base-paired and have no mismatch, even of one bp (Landegren et al. 1988). In 
ligation-RCA assay, an oligonucleotide Open Circle Probe, in which the 5’ and 3’ arms 
are complementary to the sequence flanking the SNP site, is used. If the 3’ terminal 
nucleotide of the probe is complementary to the SNP site, the hybridized arms are linked 
by the ligase enzyme and result in a circle. A circularized probe is then amplified by RCA 
driven by the DNA polymerase with strand-displacement activity and two primers, one of 
which forms a hairpin loop with fluorescent dye in one end and a quencher molecule in the 
other end. The incorporation of the primer opens the hairpin separating the fluorophore 
and quencher, and thereby gives a fluorescent signal; this procedure can lead to 1012-fold 
signal amplification, and prior PCR is not required (Faruqi et al. 2001). Different detection 
and ligation approaches have been utilized in RCA-mediated genotyping (reviewed in 
Nilsson et al. 2006), but as an example the detection of SniperTM assay from Amersham 
Biosciences is based on FRET whereas SNPWaveTM from KeyGene NV utilizes 
fluorescence detection of size separated fragments (Twyman and Primrose 2003, van Eijk 
et al. 2004). 
 
3.2.3 Ultra high-throughput genotyping 
3.2.3.1 Affymetrix microarray mapping sets 
Affymetrix offers defined sets of SNP panels for genome-wide association (GWA) 
studies. Commercially available are GeneChip 10K, 100K, and 500K sets that consist of 
approximately 10,000, 100,000, and 500,000 SNP assays, respectively, across the genome. 
Published examples using the Affymetrix 100K mapping set for GWA studies already 
exist (Klein et al. 2005, Uimari et al. 2005), and studies with the 500K are ongoing. All 
SNPs in the mapping sets are carefully selected based on accuracy, call rate, and physical 
distribution across the human genome, but not on the LD structure. The SNPs have also 
been validated across a wide range of populations. However, the average distance between 
SNPs in the 100K mapping set (23.6 kb) is not dense enough to cover most of the 
common variation in the human genome (http://www.affymetrix.com/support/technical/ 
byproduct.affx?product=100k). Conversely, the number of SNP assays in the mapping set 
500K makes GWA studies more feasible, with the average distance between SNPs being 
5.8 kb (http://www.affymetrix.com/products/arrays/specific/500k.affx).  
 
In the Affymetrix microarray mapping assays the complexity of the genome is first 
reduced by fragmenting the genomic DNA by a restriction enzyme, and then ligating 
adaptor sequences to the DNA fragments, which are then PCR amplified by universal 
primers. The usual assay-specific PCR is thus not needed. To allow efficient 
hybridization, PCR products are further enzymatically digested. The 3’ ends of the 
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fragmented amplicons are biotinylated, and then hybridized to oligonucleotide arrays. A 
streptavidin-fluorescent protein conjugate is used for staining the hybridized products. 
Arrays are scanned with scanners that read the intensity of the fluorescent signal at 
different positions on the chip. For every SNP, the array contains several probes that are 
complementary to both sense and antisense strands, and correspond to both of the two 
possible alleles. In addition, mismatch probes are used to measure the specificity of the 
binding (Affymetrix Mapping Assay manual and http://keck.med.yale.edu/affymetrix 
/AFFYgenotyping.htm). 
 
3.2.3.2 Illumina mapping sets 
Illumina’s high-throughput capacity is based on a high multiplexing level, which is 
achieved with help of microscopic beads that together with optical fiber bundles or with 
microwells etched into an array, create an array of arrays format. Illumina offers different 
SNP sets for different purposes; Golden Gate assay is mainly used for custom sets of 
SNPs, whereas Infinium I and II genotyping sets are designed for whole-genome 
association studies. 
 
The Golden Gate assay is based on allele-specific primer extension (ASPE) gapped 
ligation reaction. The assay starts with the immobilization of the genomic DNA on 
paramagnetic particles. Two allele-specific and one locus-specific oligonucleotides are 
annealed to immobilized genomic DNA, followed by the extension of allele-specific 
oligonucleotide and its ligation to the locus-specific oligonucleotide. These allele-specific 
products are PCR amplified using differentially labeled universal primers, for which the 
sequences were introduced along with the specific oligonucleotides. These amplicons are 
hybridized to their complement bead type through their unique tag sequence, which was 
introduced by the locus specific oligonucleotide. These products are then hybridized to the 
array, and fluorescence is detected. Up to 1,536 SNPs can be multiplexed in this procedure 
(Steemers and Gunderson 2005). 
 
Illumina offers several InfiniumTM genotyping arrays, which differ from each other by the 
set of SNPs. The newest assay contains over 555,000 SNP loci, which are carefully 
selected tagSNPs that should provide comprehensive genomic coverage across multiple 
populations. The Infinium assay starts with whole-genome amplification, followed by the 
enzymatic fragmentation of DNA molecules. Amplified and fragmented DNA is then 
hybridized to arrays: fragments anneal to locus-specific oligonucleotide probes, which are 
covalently linked to one of over 200,000 bead-types. In Infinium I assay, which is based 
on allele-specific primer extension (ASPE), only the perfectly matching probe is extended 
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with fluorescently stained nucleotides. The newer and more robust version, Infinium II, is 
based on single base extension (SBE), in which allelic discrimination is based on 
incorporation of differentially labeled nucleotides (Steemers and Gunderson 2005, 
Gunderson et al. 2006). 
 
3.3 Attempts to save effort: Pooled genotyping  
Although genotyping techniques have developed enormously during the last few years, 
and genotyping costs and manual work have decreased accordingly, the genotyping cost 
has still been the major problem in large-scale association studies. One of the most 
popular attempts to save effort has been a pooled genotyping strategy, in which individual 
DNA samples are mixed together and genotyped as pooled samples. This approach has 
also been referred to as “allelotyping” in the literature, because allele frequencies rather 
than genotype frequencies can be measured from pooled DNAs (Meaburn et al. 2006, 
Yang et al. 2006a). Association studies utilizing this approach can be conducted by 
preparing separate patient and control pools, and judging the association based on the 
differential allele frequencies in the pools. Even if the final conclusions would not be 
made based on estimated allele frequency differences, large-scale association studies can 
utilize this approach by doing a follow-up, in which individual samples are genotyped 
only for potentially interesting markers (Sham et al. 2002, Mohlke et al. 2002, Hinds et al. 
2004 ). Pooled DNA genotyping has also been broadly used for SNP validation to discard 
monomorphic markers (Buetow et al. 2001, Nelson et al. 2004, Yang et al. 2006b). 
 
The pooled genotyping procedure starts with the DNA pool construction. In order to make 
meaningful allele frequency estimations, each DNA sample has to be included in equal 
quantities in the pool. DNA concentration can be measured based on ultraviolet (UV) light 
spectroscopy, but as UV-light absorbance is known to be affected by impurities in DNA, a 
more accurate DNA concentration assessment, for example, with a DNA-specific dye 
PicoGreen, has been recommended (Sham et al. 2002, Norton et al. 2004). It is also 
important, before pooling, to check that samples can be amplified by PCR. After the actual 
genotyping, allele frequencies are estimated based on the relative amounts of allele-
specific products. However, the signal intensities of both alleles are very seldom equal due 
to the unequal amplification within the PCR or subsequent allele discrimination step, and 
due to, e.g., different emission energies between different fluorescent dyes (Sham et al. 
2002, Le Hellard et al. 2002). Therefore, as known to include equimolar amounts of both 
alleles, heterozygous samples should be used as correction factors. 
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It has been shown that it is possible to make accurate allele frequency estimations from 
pooled samples with a variety of SNP genotyping platforms including, for example, real-
time PCR (Germer et al. 2000), quantitative SSCP (Sasaki et al. 2001), Pyrosequencing 
(Gruber et al. 2002), primer extension using SNaPshot (Le Hellard et al. 2002) and 
MassArray MALDI-TOF (Le Hellard et al. 2002, Mohlke et al. 2002, Herbon et al. 2003). 
Pooled genotyping has also been applied to microarrays. First this was done with a custom 
set of SNPs (Lindroos et al. 2002), and recently also with Affymetrix GeneChip 10K 
(Meaburn et al. 2005) and 100K (Meaburn et al. 2006) mapping sets. Since the 10K and 
100K mapping sets seem to perform equally well in this approach, it is anticipated that the 
recently launched GeneChip 500K mapping set would be functional in pooled genotyping 
as well. This is a big step towards genome-wide association studies because it is the high 
number of genotyped individuals that are required, which make genome-wide association 
scans of complex diseases too expensive for most researchers. However, by using the 
100K mapping set, the average allele frequency difference between the estimates obtained 
from pools and actual allele frequencies in the subset of 26 individually genotyped SNPs 
was 0.036, with differences ranging from 0.008 to 0.077 (Meaburn et al. 2006). This 
indicates that allele frequency differences lower than 10% between the pools cannot, 
perhaps, be reliably estimated with these genome-wide mapping sets, or alternatively more 
replicates are needed. The standard deviation between estimated allele frequencies of 
pooled DNA obtained with other platforms have varied from 0.02 to 0.04, suggesting that 
at least four replicate measurements are recommended (Sham et al. 2002).  
 
The obvious benefits of pooled genotyping include considerable savings of time, reagent 
costs, and the amount of genomic DNA required. In spite of this, the approach has also 
been criticized because of its apparent drawbacks: rare allele frequencies are difficult to 
measure, haplotype frequencies cannot be estimated reliably, and DNA samples are 
difficult to stratify by phenotypic differences and environmental factors (Kruglyak and 
Nickerson 2001). However, it has been suggested that using three to four individuals per 
pool with a minimum of 30 pools, would make it possible to assess the haplotype 
frequencies (Yang et al. 2003). On the other hand, the benefit of pooling as few as three or 
four samples together is questionable. Although the pooling strategy is often regarded 
inappropriate for quantitative trait loci (QTL) mapping, there are studies that have 
successfully used pools of individuals in the extreme ends of a quantitative phenotype. For 
example, in a study of obesity in mice, two new obesity QTLs were found, when pools 
consisting of 14% of least obese and 14% of most obese mice were genotyped with 111 
microsatellite markers spanning the whole genome (Taylor and Phillips 1997). In the same 
way, individuals exposed to high and low levels of risk factors can be genotyped and 
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analyzed in separate pools (Weinberg and Umbach 1999). Both SNPs and microsatellites 
(Taylor and Phillips 1997, Barcellos et al. 1997) have been used in pooled genotyping; 
however, with the latter being more complicated because of the occurrence of stutter 
bands that are typical for microsatellites and may vary between markers.  
 
Although there are no considerable differences in accuracy between the different methods, 
the cost structure differs substantially. Because in pooled genotyping a small number of 
pools are genotyped preferably with a large number of markers, the benefits are not 
especially attractive in those methods that have high primer and assay set up costs. These 
include, for example, pyrosequencing and TaqMan, which utilize expensive modified 
primers (Le Hellard et al. 2002). In hybridization based reactions, except for already 
available SNP panels, each assay needs to be optimized, which also makes those assays 
less attractive for pooled genotyping. Restriction enzyme cleavage is considered to be 
unreliable for pooled genotyping (Sham et al. 2002) because of the possible partial 
cleavage. For these reasons, primer extension based methods suit probably best for pooled 
genotyping.  
 
 
4 COMPLEX DISEASES STUDIED IN THIS THESIS 
 
4.1 Pregnancy-associated venous thrombosis 
4.1.1 Introduction to venous thromboembolism 
Venous thrombosis is defined as the formation of blood clot within veins, blood vessels 
that carry blood from various tissues of the body back to the heart. Thrombus forming in 
the superficial vein is considered to be quite harmless. In contrast, deep vein thrombosis, 
formation of a thrombus in a large vein, usually in the leg, thigh, or pelvis, is a serious 
condition; the thrombus in a deep vein may break off and travel through the bloodstream 
finally into the lungs causing pulmonary embolism, which can be fatal. The main 
pathopysiological causes of venous thromboses include damage of the vessel wall, 
alterations in the blood flow, and increase in blood coagulability, the latter of which is 
likely to reflect genetic etiology (Lensing et al. 1999, Kyrle and Eichinger 2005). The term 
venous thromboembolism commonly comprises both the deep venous thrombosis (DVT) 
and pulmonary embolism (Blann and Lip 2006). Venous thromboembolism is most 
common among elderly people, but the age of onset can vary. In addition, pregnancy, 
trauma, surgery, malignancy, immobilization, use of oral contraceptives, or superficial 
vein thrombosis are known to increase the risk of venous thromboembolism (Lensing et al. 
1999, Kyrle and Eichinger 2005, Heit 2006). 
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4.1.2 Venous thrombosis during pregnancy and puerperium 
The increased risk of deep venous thrombosis (DVT) during pregnancy has been 
explained by changes in blood composition, such as an increase in coagulation factors, 
decrease in protein S, and an inhibition of fibrinolysis (McColl et al. 1997). Venous 
thromboembolism during pregnancy and puerperium is a serious medical condition, which 
causes significant maternal morbidity (van Korlaar et al. 2003, van Korlaar et al. 2004, 
Walker 2003) and is one of the leading causes of maternal death throughout the developed 
world (Cooper et al. 2002, Erkkola 1994, Greer 1999, Walker 2003). In previous studies 
the estimated incidence of pregnancy-associated DVT has varied from 71 – 85 per 
100,000 pregnancies (McColl et al. 1997, Simpson 2001, Andersen 1998). It is well 
established that inherited thrombophilia is a multifactorial disorder caused by the 
interaction of environmental and genetic risk factors (Rosendaal 1999). The environmental 
factors that have been suggested to further increase the risk of DVT during pregnancy and 
puerperium include Non-O blood group, high body mass index (BMI), advanced age, 
smoking, high parity, multiple pregnancies, and caesarean section (Greer 1999, McColl et 
al. 1997, Simpson 2001, Walker 2003, Danilenko-Dixon et al. 2001, Larsen et al. 2005, 
Ros et al. 2002). 
 
4.1.3 Genetic risk factors for venous thrombosis 
Since increased blood coagulability is one of the main causes of venous thrombosis 
(Lensing et al. 1999, Kyrle and Eichinger 2005), quite obvious candidate genes are those 
encoding proteins involved in blood coagulation. Enzymatic reactions in the coagulation 
cascade involve a series of coagulation factors, which interact with one another to keep the 
blood coagulation balanced. Coagulation factors are named by the roman numerals from I 
to XIII that indicate the order in which the various factors were discovered, and thus they 
do not show where in the cascade the factor performs its action. Alongside with the roman 
numerals, several coagulation factors also have names that describe their function, as 
shown in Table 4 (Giangrande 2003, Ganong 2005a).  
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Table 4. Coagulation factors and selected regulatory proteins in blood coagulation cascade 
(Giangrande 2003, Ganong 2005a). 
Factor Synonyms/action 
Factor I Fibrinogen 
Factor II Prothrombin 
Factor III Thromboplastin, tissue factor 
Factor IV Calcium ions 
Factor V Proaccelerin 
Factor VI Activated V (Va), this numeral is no longer used 
Factor VII Proconvertin, stable factor 
Factor VIII Antihaemophilic factor 
Factor IX Plasma thromboplastin component 
Factor X Stuart-Power factor 
Factor XI Plasma thromboplastin antecedent 
Factor XII Hageman factor 
Factor XIII Fibrin stabilizing factor 
Regulatory proteins:  
Protein S Cofactor for activated protein C 
Protein C Inactivates Va and VIIIa 
Thrombomodulin Binds to thrombin and thereby activates Protein C 
Antithrombin III Inhibits IIa, Xa, and other proteases 
Tissue factor pathway inhibitor 
(TFPI) 
Inhibits VIIa-related activation of IX and X after its original 
initiation. 
 
High plasma levels of the coagulation factors FVIII, FIX, and FXI have been associated 
with an increased risk of venous thromboembolism, but the possible underlying genetic 
defects have not been identified. Various sporadic mutations in antithrombin, protein C 
(PROC), or protein S genes have been shown to have an impact on blood coagulation, but 
they are so rare that they can explain only a small fraction of thromboses. The major 
heritable forms of thrombophilia include polymorphisms in procoagulant factors, 
especially Factor V Leiden (FVL) (G1691A; Arg506Glu) and the prothrombin (FII) 
G20210A gene polymorphisms. In addition, polymorphisms in FXII, FX, and FVII genes 
have been studied, but they do not seem to contribute to venous thromboembolism 
(reviewed in Endler and Mannhalter 2003, Robertson et al. 2006). The following seven 
mutations or polymorphisms listed in Table 5 have been extensively studied and variably 
associated with an increased risk of DVT.  
 
Table 5. Polymorphisms variably associated with venous thromboembolism.  
Gene Polymorphism Amino acid change Reference 
FII G20210A 3’ untranslated region Poort et al. 1996 
FV F V Leiden; G1691A Arg506Glu Bertina et al. 1994 
FV F V R2-allele; A4070G His1299Arg Lunghi et al. 1996 
FVIII exon 2, codon 34 G→T Val34Leu Mikkola et al. 1994 
MTHFR C677 T Ala223Val Frosst et al. 1995 
PROC T 8853G Trp380Gly Levo et al. 2000 
TFPI C536 T Pro151Leu Kleesiek et al. 1998 
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The risk for venous thrombosis caused by the Factor V Leiden (FVL) (G1691A; 
Arg506Glu) polymorphism in coagulation factor V is well established. FVL causes 
activated protein C resistance and thereby increases the risk for venous thrombosis 
(Dahlbäck et al. 1993, Bertina et al. 1994, Lane et al. 1996). FVL has also been associated 
with DVT during pregnancy (McColl et al. 1997, Grandone et al. 1998, Gerhardt et al. 
2000, Martinelli et al. 2002), although the pregnancy-associated risk is not settled in large 
population-based studies. R2 allele in the same gene (A4070G; His1299Arg) (Lunghi et 
al. 1996) has been inconsistently associated with activated protein C resistance and its role 
in DVT is controversial (Castaman et al. 2003). FII G20210A mutation in the 3’-
untranslated region of the prothrombin gene (Poort et al. 1996) has been associated with 
an elevated plasma prothrombin level and venous thrombosis. It is the second genetic 
defect, which has been convincingly associated with DVT (reviewed in Endler and 
Mannhalter 2003), although the evidence of its role in pregnancy is scarce (Grandone et al. 
1998, McColl et al. 2000, Gerhardt et al. 2000, Martinelli et al. 2002). In Finland, a single 
point mutation in the protein C (PROC) gene (T8853G; Trp380Gly) explains the majority 
of type II protein C deficiency (Levo et al. 2000) that is an established risk factor for 
venous thrombosis. A point mutation (C536T; Pro151Leu) in the tissue factor pathway 
inhibitor (TFPI) gene (Kleesiek et al. 1998) has been suggested to increase the risk for 
venous thrombosis, although the mechanism is not clear (Kleesiek et al. 1999). TFPI and 
PROC mutations have not been previously studied in pregnancy associated thromboses. In 
contrast to the other listed polymorphisms, the common G to T substitution in codon 34 of 
exon 2 in the factor XIII gene (FXIII Val34Leu) (Mikkola et al. 1994) has been associated 
with a decreased risk for venous thrombosis (Catto et al. 1999, Franco et al. 1999). In 
addition to polymorphisms in coagulation factors, a common polymorphism in the 
methylenetetrahydrofolate reductase (MTHFR) gene (C677T; Ala223Val) (Frosst et al. 
1995) has been associated with venous thrombosis, also during pregnancy, but the results 
have again been inconsistent (den Heijer et al. 2005, Grandone et al. 1998, Gerhardt et al. 
2000, Gerhardt et al. 2003, McColl et al. 2000). Methylenetetrahydrofolate reductase 
catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a 
cosubstrate for homocysteine remethylation to methionine. The variant allele generates a 
thermolabile enzyme with a reduced enzyme activity, and has been speculated to represent 
a genetic risk factor in vascular disease, since the carriers have elevated plasma 
homocysteine levels (Frosst et al. 1995). 
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4.2 The link between small birth size and adult disease 
4.2.1 Epidemiological findings 
In the late 1980s David Barker and co-workers reported an interesting finding; among 
nearly 6000 men born during 1911-30 in Hertfordshire, England, the highest death rates 
from ischemic heart disease were observed in men with the lowest weights at birth (Barker 
et al. 1989). Later they showed that low birth weight is also associated with type 2 
diabetes (Barker et al. 1993). Based on these, and similar observations, Barker and 
colleagues proposed a “fetal programming hypothesis” to explain the link between low 
birth weight and non-communicable diseases in adult life. Since then a large number of 
epidemiological studies all over the world have shown strong associations between small 
birth size and late-onset diseases, such as type 2 diabetes (Lithell et al. 1996), 
cardiovascular diseases (Stein et al. 1996, Rich-Edwards et al. 1997, Eriksson et al. 2001), 
central obesity (reviewed in Oken and Gillman 2003), hypertension (Law et al. 1993, 
Curhan et al. 1996), and depression (Gale and Martyn 2004, Thompson et al. 2001). As an 
example, in the Helsinki Birth Cohort Study of 4360 men who were born in 1934-44 in 
Helsinki, deaths from coronary heart disease were associated with small birth size; men 
whose birth weight was < 2500 g had a hazard ratio for coronary heart disease of 3.63 
(95% CI 2.02 to 6.51) compared to the group with a birth weight > 4000 g (Eriksson et al. 
2001). These associations are seen across the normal range of birth weights and among 
small-for-gestational-age babies rather than among extremely small or prematurely born 
babies. However, not only fetal but also childhood growth has been shown to affect the 
disease risk in later life. In studies of the Helsinki Birth Cohort, Barker and co-workers 
showed that those who developed coronary heart disease later in life were small at birth, 
thin for the first two years of life, and thereafter grew more rapidly and reached the 
average values by 11 years of age (Barker et al. 2005). The importance of this “catch-up 
growth” in predisposing to adult type 2 diabetes has also been shown (Forsén et al. 2000). 
 
4.2.2 Fetal programming hypothesis  
According to Barker’s fetal programming hypothesis, small birth size of full term babies is 
seen as an indication of growth restriction caused, for example, by malnutrition. A poorly 
nourished fetus directs its scarce nutrients to the brain at the other organs’ expense. 
Consequently, the fetus adapts to survival under conditions of poor nutrition, which 
permanently change the structure and function of critical organs and hence the physiology 
and metabolism of the body. This kind of adaptation becomes especially disadvantageous 
if prenatal malnutrition is changed to adequate nutrition in postnatal environment. This 
predisposes individuals to cardiovascular, metabolic, and endocrine diseases in adult life, 
i.e., the susceptibility to adult diseases is “programmed” during early life (Hales and 
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Barker 1992, Barker 1998, Barker 1999, Hales and Barker 2001). In addition to fetal 
malnutrition, it is believed that increased cortisol or other glucocorticoid exposure during 
gestation as a result of maternal stress or maternal glucocorticoid administration can 
trigger the programming of glucocorticoid action, leading to adult metabolic diseases 
(reviewed in Stocker et al. 2005). 
  
In addition to epidemiological findings, extensive animal research supports the fetal 
programming hypothesis; prenatal restriction of nutrients in rats leads, for example, to 
altered glucose tolerance (Langley et al. 1994, Vickers et al. 2000), which is even more 
pronounced if previously malnourished animals are fed with a high-fat diet (Wilson and 
Hughes 1997). Prenatal protein restriction also leads to the reduced growth of organs such 
as pancreas, spleen, muscle, and liver (Desai et al. 1996), and to decreased pancreatic β-
cell proliferation, islet size, islet vascularization (Snoeck et al. 1990), and islet cell 
function (Cherif et al. 1998). Similar effects are caused by other interventions including 
maternal glucocorticoid administration and maternal stress (Lindsay et al. 1996, Stocker et 
al. 2005). These physiological alterations are one possible mechanism behind the 
programming phenomenon.  
 
In humans, the effects of maternal nutritional deprivation during pregnancy have been 
studied in people born during and after the brief, but severe, Dutch famine in 1944-1945 
(Stein and Susser 1975). Studies on this birth cohort have shown that maternal 
malnutrition during gestation predisposes the fetus to various disorders in adult life, such 
as coronary heart disease, obesity, obstructive airways, microalbuminuria, and impaired 
glucose tolerance. However, depending on whether nutritional deprivation occurs in the 
early, mid, or late gestation, different organ systems are affected (reviewed in Painter et al. 
2005). Again, transition from undernourishment during fetal life to adequate nutrition later 
on has probably been important in predisposing to these adult diseases. Further support for 
the fetal programming hypothesis, which has been recently redefined as the 
“developmental origins of health and disease” hypothesis (Gillman 2005), is provided by 
studies in monozygotic twins showing that the smaller twin at birth is more likely to 
develop type 2 diabetes (Poulsen et al. 1997) and hypertension (Poulter et al. 1999), 
although this has not been consistently reported (Baird et al. 2001). 
 
4.2.3 Genetic hypothesis 
The genetic hypothesis, which suggests that both the birth size and late-onset disease are 
simply two independent consequences of the same genotype, was originally presented in a 
more specific form, as the “fetal insulin hypothesis”. This hypothesis proposes that genetic 
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factors determine insulin resistance, which results in low birth weight (Hattersley and 
Tooke 1999, Frayling and Hattersley 2001). Studies on gene knock-out mice have shown 
that fetal growth and birth size are affected by insulin metabolism related genes (reviewed 
in Ong and Dunger 2004). It is also well known that rare mutations in human genes 
affecting glucose metabolism, such as the insulin receptor, glucokinase, insulin-like 
growth factor 1, and insulin-like growth factor 1 receptor genes, result in retarded fetal 
growth (Dunger et al. 2006). Moreover, a common polymorphism in the glucokinase gene 
was recently shown to be associated with both increased fasting glucose and increased 
birth weight in the offspring of females (Weedon et al. 2005). However, studies on 
monozygotic twins, disconcordant for diabetes, have shown that the association between a 
low birth weight and type 2 diabetes cannot be explained only by genetic factors (Poulsen 
et al. 1997, Bo et al. 2000). Most of the above mentioned mutations are also too rare to 
explain the common link between a small birth size and adult type 2 diabetes and related 
diseases. 
 
4.2.4 Genetic factors that modify the link between fetal growth and adult 
disease 
It is also possible that the link between fetal growth and adult disease is explained by the 
synthesis of the fetal programming hypothesis and the genetic hypothesis, i.e., an 
individual’s susceptibility for a specific mechanism of programming would be affected by 
a certain genotype. The phenomenon of the same genotype giving rise to different 
phenotypes in different conditions during development has been referred to as “phenotypic 
plasticity” (Barker 2002). Evidence for this kind of genotype – intra-uterine environment 
interaction in relation to adult diseases is beginning to emerge. Candidate gene studies on 
the Helsinki Birth Cohort of 500 subjects born between 1924 and 1933 have revealed 
interesting gene-environment interactions in relation to well-known common 
polymorphisms of the peroxisome proliferator-activated receptor gamma (PPARG) gene 
(Eriksson et al. 2002a, Eriksson et al. 2003), which has been consistently associated with 
type 2 diabetes (Altshuler et al. 2000, Stumvoll and Haring 2002), and plasma cell 
glycoprotein 1 (PC-1) gene (Kubaszek et al. 2004). Eriksson and colleagues found that the 
association between small body size at birth and late life insulin resistance was seen only 
in individuals homozygous for the common high-risk PPARG Pro12Pro allele. On the 
other hand, the association of this allele with increased insulin resistance and elevated 
insulin concentrations was seen only in subjects of low birth weight (Eriksson et al. 
2002a) and length (Eriksson et al. 2003). They also observed a similar association between 
birth size and a common polymorphism of the PC-1 gene, which is known to inhibit the 
autophosphorylation of insulin receptor; the association between the Lys121Gln 
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polymorphism of the gene and late life insulin sensitivity and type 2 diabetes was strongly 
modified by length at birth (Kubaszek et al. 2004). These findings can be interpreted as 
examples of interactions between the genotype and the intrauterine environment with 
resulting changes in gene expression, perhaps via DNA methylation. Altered gene 
expression during the development may result in, for example, an altered structure of the 
affected organs or changes in feedback systems, thereby altering hormone and growth 
factor levels permanently (Hales and Barker 1992, Barker 1998). 
 
4.2.5 Angiotensin converting enzyme as a possible candidate gene 
Angiotensin-converting enzyme (ACE) is a key enzyme in the renin-angiotensin system, 
which regulates the blood pressure and blood volume in the body. ACE exerts its effects 
mainly by catalyzing the conversion of inactive angiotensin I to active angiotensin II, but 
also by inactivating the vasodilatory peptide bradykinin. The inactivation of bradykinin 
belongs to another hormonal system, the so-called kinin-kallikrein cascade. Angiotensin II 
is a potent vasopressor and aldosterone-stimulating peptide, whereas bradykinin is a potent 
vasodilator (Sayed-Tabatabaei et al. 2006). The schematic picture of the function of ACE 
on these two hormonal systems is shown in Figure 3. 
 
 
Figure 3. The role of angiotensin-converting enzyme in the kinin-kallikrein and renin-
angiotensin systems (modified from Sayed-Tabatabaei et al. 2006). 
 
In addition to being a potent vasoconstrictor, Angiotensin II triggers the release of 
aldosterone from adrenal cortex, leading to the reabsorbtion of more sodium and water 
from the urine in the tubules of the kidneys. This increases the amount of fluid in the 
blood and leads to an increased blood pressure. Angiotensin II also mediates cell growth 
and proliferation by stimulating various cytokines and growth factors (Sayed-Tabatabaei et 
al. 2006). 
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The ACE gene, which is located on chromosome 17q23, has a common insertion/deletion 
(I/D) polymorphism, defined by the presence or absence of a 287 bp fragment inside 
intron 16. The D allele is associated with higher circulating and tissue ACE levels, which 
is believed to explain about half of the inter-individual differences observed in ACE levels 
(Rigat et al. 1990, Danser et al. 1995). In addition to altered ACE levels, the D allele has 
been associated with an increased risk of micro- and macrovascular complications of 
type 2 diabetes in a large number of studies (Kennon et al. 1999, Ruiz et al. 1994, Huang 
et al. 1998, Sayed-Tabatabaei et al. 2006). However, these findings have been inconsistent 
(Morgan et al. 2003, Sayed-Tabatabaei et al. 2006). The possibility that the size at birth, a 
marker of an adverse intrauterine environment, could modify the risk associated with the 
I/D polymorphism was supported by a study, which showed that among a group of young 
adults, the I allele was related to a greater insulin secretion only in those born very small, 
but not in those born with the appropriate size for gestational age (Cambien et al. 1998). It 
has not been reported whether a similar effect is seen across the normal range of birth 
weights. The recent evidence suggests that the I/D polymorphism itself may not be a 
functional polymorphism but may be in LD with a functional one (Zhu et al. 2000, 
McKenzie et al. 2005). Due to the fact that the exact causative polymorphisms may not 
have been found and because of the tight LD in the ACE gene region in at least Caucasian 
populations, researchers have continued to use the I/D polymorphism as a marker in 
association studies to assess the link between the variant form of the ACE gene and the 
pathophysiological conditions (Sayed-Tabatabaei et al. 2006). 
 
4.2.6 Glucocorticoid receptor as a possible candidate gene 
Glucocorticoids, which include the stress hormone cortisol, have an important role in the 
regulation of glucose metabolism and fetal development. Glucocorticoids mediate their 
cellular action by complexing with the cytoplasmic glucocorticoid receptor (GR), which in 
turn translocates to the nucleus and functions as a transcription factor. Even though 
glucocorticoids are essential for life, responses to glucocorticoids vary extensively among 
individuals and even among tissues (Lu and Cidlowski 2006). Different GR isoforms and 
polymorphisms in the GR gene are likely to reflect the variable responsiveness to 
glucocorticoids, but also other mechanisms, such as fetal programming, may underlie this 
variability. Therefore, GR is an attractive candidate gene to mediate and modify the link 
between fetal growth restriction, as shown by the reduced birth size and type 2 diabetes 
related diseases in adult life. 
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4.2.6.1 Programming of the hypothalamic-pituitary-adrenal-axis 
Increased adult plasma cortisol levels have been associated with low birth weight (Phillips 
et al. 1998, Phillips et al. 2000), as well as with an increased risk for impaired glucose 
tolerance, hypertension, and metabolic syndrome (Andrews et al. 2002, Andrew et al. 
2002). Reduced birth weight is also caused by glucocorticoid treatment during pregnancy, 
both in animal models (Reinisch et al. 1978, Ikegami et al. 1997) and in humans (French 
et al. 1999, Bloom et al. 2001). Based on these associations, the programming of the 
hypothalamic-pituitary-adrenal-axis (HPAA) function, which regulates the glucocorticoid 
metabolism as illustrated in Figure 4, has been suggested to be a key mediator in the link 
between fetal growth restriction and adult metabolic diseases. It has been shown that the 
set point of this stress response mediating HPAA can be altered during early life by 
prenatal nutrient restriction or exposure to synthetic glucocorticoids. This is supported by 
recent studies in humans showing that maternal psychosocial stress (Gutteling et al. 2004, 
Gutteling et al. 2005, O’Connor et al. 2005) and low birth weight (Phillips et al. 2000, 
Kajantie et al. 2002) are associated with alterations in HPAA function.  
 
 
 
Figure 4. The regulation of the hypothalamic-pituitary-adrenal axis function. The 
hypothalamus secretes corticotrophin releasing hormone (CRH) in response to, for 
example, stress (+) and the sleep (-) /wake (+) cycle. CRH stimulates the anterior pituitary, 
resulting in the release of adrenocorticotrophin (ACTH). ACTH travels in the blood 
stream and stimulates the adrenal glands to produce and release cortisol, which in turn has 
multiple metabolic effects (Modified from Brook and Marshall 2001). 
 
The suggested mechanism underlying the HPAA programming involves long-term 
changes in the expression of the glucocorticoid action-mediating glucocorticoid receptors, 
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possibly based on gene methylation (reviewed in Phillips and Jones 2006). Support for 
this has been obtained from animal studies showing that prenatal maternal stress results in 
a reduced hippocampal GR expression in rat offspring, while maternal nutrient restriction 
shows modified HPAA function and a significantly reduced GR expression in the anterior 
pituitary, but not in the hippocampus of adult guinea pig offspring (reviewed in Kapoor et 
al. 2006). However, the main glucocorticoid of rodents is corticosterone, rather than 
cortisol, as it is in humans. The role of glucocorticoids in the programming of HPAA 
function may have a large impact on health, because pregnant women who are at risk of 
preterm labor are routinely treated with synthetic glucocorticoids to enhance the 
maturation of lungs in newborns (Ballard and Ballard 1995). 
 
4.2.6.2 Variant forms of the glucocorticoid receptor gene 
The GR gene is composed of 9 exons, of which exon 1 and 9 are alternatively spliced. As 
a result of alternative splicing, there are two main GR isoforms, alpha and beta, which 
differ in their carboxyl termini (exon 9). In addition, several less abundant GR splice 
variants exist (Lu and Cidlowski 2004). GR-alpha regulates the expression of 
glucocorticoid-responsive genes, while GR-beta is transcriptionally inactive but functions 
as a dominant negative inhibitor of GR-alpha (Oakley et al. 1999). GR-alpha is 
ubiquitously expressed, whereas GR-beta has a more tissue specific expression. There are 
several different transcription start codons resulting in different exon 1 isoforms, driven by 
different promoters. The alternative first exons encode only the 5’ untranslated region; 
therefore they do not affect the protein structure, but instead play an important role in the 
tissue specific GR expression (Zhou and Cidlowski 2005). 
 
The following polymorphisms in the GR gene have been studied extensively and are 
speculated to underlie the variable response to glucocorticoids between individuals: 1) the 
rare ER22/23EK polymorphism (MAF 1.6%; Stevens et al. 2004) in exon 2 that encodes 
the first transactication domain, consisting of two SNPs that are in perfect LD with each 
other, R23K being the amino acid altering SNP; 2) another polymorphism in exon 2, 
N363S, substituting the amino acid asparagine to a serine with a reported MAF in 
European population of 3.0% (Dobson et al. 2001); and 3) the more frequent BclI 
restriction site polymorphism (reported MAF of 37%; Wüst et al. 2004), formerly known 
as a 2.3 kb and 4.5 kb allele, but recently identified to constitute of a C to G substitution in 
the intron 2,646 bp downstream from exon 2 (van Rossum et al. 2003, Fleury et al. 2003). 
ER22/23K seems to be associated with favorable phenotypes, such as a greater height, 
muscle mass and muscle strength in young males and a smaller waist and hip 
circumference in young females (van Rossum et al. 2004), lower fasting insulin and LDL 
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cholesterol levels, and higher serum cortisol concentrations after dexamethasone 
suppression test, indicating a decreased sensitivity towards glucocorticoids (van Rossum 
et al. 2002). On the contrary, N363S and BclI polymorphisms have been associated with 
an increased sensitivity towards glucocorticoids (Huizenga et al.1998, van Rossum et al. 
2003), leading to higher cortisol action, and thereby a harmful cardiovascular and 
metabolic profile. In addition, N363S has been associated with increased salivary cortisol 
responses to stress (Wüst et al. 2004), coronary artery disease (Lin et al. 2003), central 
obesity in men (Dobson et al. 2001), and higher BMI (Huizenga et al. 1998, Lin et al. 
1999). The 4.5 kb (G) allele of the BclI polymorphism has been associated with a 
diminished cortisol response to stress (Wüst et al. 2004), and lower BMI in elderly males 
(van Rossum et al. 2003), but also with elevated BMI (Rosmond et al. 2000) and 
abdominal obesity (Buemann et al.1997). All of the above mentioned findings have 
typically been inconsistent (Koper et al. 1997, Echwald et al. 2001), which may be due to 
too small sample sizes or the lack of environmental factors taken into account. The 
ER22/23EK and N363S polymorphisms are also too rare to have notable population 
attributable risks or to reach the statistical significance, unless very large sample sizes are 
studied. 
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AIMS OF THIS STUDY 
 
1. To set up SNP genotyping techniques at the Finnish Genome Center and to 
evaluate their performance. 
 
2. To test pooled genotyping as a screening method for large-scale association 
studies.  
 
3. By utilizing large epidemiological cohorts in candidate gene association studies, to 
identify genetic factors involved in: 
 
a. Predisposition to pregnancy-associated deep venous thrombosis. 
 
b. Mediation or modification of the well-known association between small 
body size at birth and adult diseases, such as type 2 diabetes and impaired 
glucose tolerance. 
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MATERIALS AND METHODS 
 
 
1 STUDY SUBJECTS 
 
1.1 Genotyping set-up (unpublished results) 
After initial testing with Centre d'Etude du Polymorphisme Humain (CEPH) samples, 
genotyping was performed on various sample sets, including samples described in sections 
1.2 (Pregnancy complications) and 1.3 (The Helsinki Birth Cohort), and additional sample 
sets including altogether 2,248 DNA samples from the “Generale” study (unpublished), 
which is a European multi-center prospective study concerning both genetic and 
environmental risk factors for age-related atherosclerosis and cardiovascular events. The 
Generale sample set included 713 individuals from Kuopio, Finland, 464 individuals from 
Edinburgh, UK, 329 individuals from Greifswald, Germany, 634 individuals from 
Tromsoe, Norway, and 108 individuals from Vicenza, Italy. In addition, 826 samples from 
the Finnish Asthma study (Laitinen et al. 2004) and 93 samples from the Finnish Dyslexia 
study (unpublished), were genotyped. The statistics shown in the results of the SNP 
genotyping set-up are derived from these a total of 6,603 samples, which were genotyped 
with sets of 7 to 52 markers, altogether giving over 66,000 genotypes (see Table 6). 
 
Table 6. Summary of the genotyped samples and SNPs. 
Project Genotyping 
technique 
Number of 
samples 
Number of markers Successful 
genotypes 
Reference 
Pregnancy 
complications 
PCR-RFLP 2,936 7 20,109 Study II 
Generale PCR-RFLP 2,248 7 14,733 Unpublished 
The Helsinki 
Birth Cohort 
SNuPeTM 500 17 (whole sample set) 
21* 
10,057 Study IV and 
unpublished 
The Helsinki 
Birth Cohort 
PCR (ACE 
I/D) 
500 1 492 Study III 
Asthma SNuPeTM 
 
826 12 (whole sample set) 
15* 
11,220 Laitinen et al. 
2004 
Asthma MassArray  360 15 5,109 Laitinen et al. 
2004 
Dyslexia SNuPeTM 93 52 4,542 Unpublished 
* Pilot of 93 samples to discard monomorphic and unreliable markers 
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1.2 Pregnancy-associated venous thrombosis (II) 
As described in (II), 100,000 consecutive pregnancies in Finland during 1997-1998 were 
ascertained for various pregnancy complications, including venous and arterial 
thrombosis, pre-eclampsia, premature birth, birth of small-for-gestational-age babies, 
miscarriage, and stillbirth. Altogether 2,292 samples, including cases and controls (blinded 
for disease status at the genotyping stage), in addition to a population sample of 644 
consecutive first-time blood donors from different parts of Finland were genotyped. These 
genotypes are included in the evaluation of genotyping performance in the section 
describing the genotyping set-up. 
 
The controls were randomly selected among 93,935 pregnancies where no pregnancy 
complications occurred. Among these, 641 women fulfilled the selection criteria and were 
willing to participate. The sub study included in this thesis (II) concerns risk factors for 
pregnancy-associated deep venous thromboses. In 34 women (cases) an objectively 
diagnosed deep venous thrombosis (DVT), pulmonary embolism, or sinus thrombosis had 
occurred during the index pregnancy or puerperium. The patient and control selection 
process is explained in more detail in Study II. The study was approved by the ethics 
committee, and all participants gave informed consent. 
 
1.3 Helsinki Birth Cohort (III and IV) 
The total study cohort consists of 7,086 individuals born as singletons at Helsinki 
University Central Hospital during 1924-1933. Their birth records included data for 
gestational age, weight, length, and head circumference at birth. From this cohort, 500 
individuals were clinically examined at the age of 65 to 75 years, providing detailed recent 
metabolic phenotypes that can be linked to the early growth data. The clinical examination 
included standard anthropometric measurements, blood pressure, a 2-hour oral glucose 
tolerance test (75 g glucose) with glucose and insulin measurements, the measurement of 
serum cortisol and corticosteroid binding globulin (CBG) concentrations, and a blood 
sample for DNA extraction. The clinical examination is described in more detail 
elsewhere (Eriksson et al. 2002b, Kajantie et al. 2002). The study was approved by the 
ethics committee, and all participants gave informed consent. 
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2 GENOTYPING  
 
2.1 PCR-RFLP (I, II, unpublished results) 
An improved traditional SNP genotyping method based on polymerase chain reaction 
(PCR) followed by restriction fragment length polymorphism (RFLP) was set up for 
medium-throughput genotyping. PCR assays were multiplexed by two and performed on 
384-well microtiter plates in a total volume of 5 µl to increase capacity and minimize 
reagent consumption. An additional restriction site was included in each PCR product to 
serve as an internal control site for the completeness of the digestion reaction. PCR 
primers were designed using the Primer3 program (Rosen and Skaletsky 1996, 1997). 
Some of the primer sequences were modified to create an artificial digestion site, if the 
natural digestion site did not exist. A fluorescent label (6-FAM, NED or HEX) was 
included in either the forward or reverse primer (primer sequences shown in Table 7). 
PCR assays were performed in a total volume of 5 µl containing 20 ng human genomic 
DNA, 250 µM of each dNTP, 3.0 mM MgCl2, 1xPCR-buffer, 0.2 units ampli-Taq Gold 
DNA-polymerase (all from Applied Biosystems, Foster City, CA, USA) and 0.2-0.8 
pmoles of each primer (Sigma-Genosys, Cambridge, UK). The thermal cycling was 
performed on a GeneAmp PCR system 9700 (Applied Biosystems) in the following 
conditions: 95°C for 10 min, 30 cycles at 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s, 
followed by a final extension at 72°C for 7 min.  
 
The PCR products were digested with 1 U of the specific restriction enzyme (New 
England Biolabs, Beverly, MA, USA) (shown in Table 7). Digestion reactions were 
performed at 37°C for 3 h, followed by incubation at 60-65°C for 3 h. Digested PCR 
products were pooled together to obtain a mixture containing 7 to 9 markers per one 
sample and separated in 5% Long Ranger / 6M urea gels using the ABI PRISM 377 
(Applied Biosystems) DNA sequencer with 1xTBE as the electrophoresis buffer and 500 
ROX as a size standard (Applied Biosystems). The data was analyzed using the Genescan 
3.1 and Genotyper 2.5 software (Applied Biosystems). 
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Table 7. Primer sequences used in PCR-RFLP genotyping. The underlining indicates the 
modified primer sequences, which are designed to create an artificial restriction site. 
Project SNP Forward primer   5’→ 3’ 
Reverse primer  5’→ 3’ 
Restriction 
enzyme 
Generale GPX1, Pro197Leu ACGATGTTGCCTGGAACTTT 
FAM-CAGAGACTGGGATCAACAGGA 
ApaI 
 GSTP1, Ala113Val ATTTGTGTCGGGTGGGTAAG 
NED-CTCACCTGGTCTCCCACAAT 
AciI 
 GSTP1, Ile104Val GGCAGTCTCTCATCCTTCCA 
NED-AGCCCCTTTCTTTGTTCAGC 
BsmAI 
 MPO (-463)G/A HEX-AAATCTTGGGCTGGTAGTGC 
AAGAACGCGGGCCTCTAGCCACATCATCAA 
AciI 
 MPO, Arg569Trp GTCCCTGGGGTCATGTAGTG 
HEX-CATGTTCAGAGCAGGCAGGT 
NciI 
 SOD2, Ala16Val FAM-GACTGACCGGGCTGTGCT 
CGGAACCGGTACAAATACGA 
BsaWI 
 XDH, c2567del HEX-ACGGGATGATGTGGTGTTCT 
CCCCCCCAATTGTCCACCTCAAGAGCCACAATT 
MfeI 
Pregnancy 
complications 
FVL,Arg506Glu GCCCAGTGCTTAACAAGACCA 
HEX-TTTCTGAAAGGTTACTTCAAGGACA 
MnlI 
 FII, G20210A 6FAM-CAGAAGGTCATTGATCAGTTTGG 
ATAGCACTGGGAGCATTGAAGC 
HindIII 
 FVR2, His1299Arg ACCTCAGCCACACGACTCTC 
HEX-GCAAAGAGGGGCATCTCAC 
RsaI 
NdeI 
 PROC, Trp380Gly 6FAM-ATGGTCGCCTCCTTCCAC 
CATCCATTGCCATGCAAAA 
AluI 
 F XIII, Val34Leu GGGGCGCGCCACAGTGGAGCTTCAGCGC 
6FAM-CCCAGAGTGGTGGGGAAG 
BstUI 
 TFPI, Pro151Leu NED-CGTTCATGAGTCCAAATATGAG 
TCTTACCAAAAAGACTGGGAACC 
BsRI 
 MTHFR, Ala223Val NED-TGTCATCCCTATTGGCAGGTT 
GGGAGCTTATGGACTCTCCTG 
HinfI 
 
2.2 SNuPeTM (I, IV, unpublished results) 
The second genotyping method was based on single nucleotide primer extension 
(SNuPeTM by Amersham Biosciences, Piscataway, NJ, USA). In addition to work-flow 
set-up, we participated in the development of the chemistry and the allele-calling software 
by carrying out the alpha and beta tests. 
  
A fragment containing the polymorphic site was PCR amplified with primers designed to 
amplify PCR products greater than 300 bp in length. All the primers were designed using 
the Primer3 program (Rosen and Skaletsky 1996, 1997), and are shown in Table 8 
(because of the large number of conducted assays, only the primers used in Study IV are 
shown; primer sequences used in pooled genotyping are shown in Study I). PCR assays 
were performed in a total volume of 5 µl, containing 20 ng of human genomic DNA, 250 
µM of each dNTP, 3.0 mM MgCl2, 1xPCR-buffer, 0.2 units ampli-Taq Gold DNA-
polymerase (all from Applied Biosystems), and 0.5 pmol of each primer (Sigma-Genosys). 
The PCR assays were performed on a GeneAmp PCR system 9700 (Applied Biosystems). 
The thermal cycling conditions were 95°C for 10 min, 30 cycles at 95°C for 30 s, 60°C for 
30 s, and 72°C for 30 s, followed by a final extension at 72°C for 7 min. 
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Table 8. Primer sequences used in SNuPeTM genotyping. Only the primers used in Study 
IV are shown. 
dbSNP Status Forward primer  5’→ 3’ 
Reverse primer  5’→ 3’ 
Internal extension primer  5’→ 3’ 
 
rs6196 tagSNP 
 
CAACTGCTTCTGTTGCCAAG 
TTCTCTTGCAGGTGGTTGAA 
CCAATCAGATACCAAAATATTCAAA 
rs258813 tagSNP 
 
GCGCCTTTTTCTCCCATAAT 
TGAAGGCCTAGAAACAAAGGTT 
AAGAAAGCTAACTACAGTGATTTTGTC 
rs33391 uninformative 
 
ACAGTGACACCAGGGTAGGG 
TTGGGAATAGGTTCCTCTGG 
AGAAACCTCTGAAAATCCTGGTAA 
rs6188 in perfect LD 
with rs258813 
ACAGTGACACCAGGGTAGGG 
TTGGGAATAGGTTCCTCTGG 
TTTTCGAGCTGTGGGTATTTAAA 
rs4986593 tagSNP 
 
GTGAACCAGAACCACACCATT 
CCTGTTGTTGCTGTTGAGGA 
CTCACAGTGAACTCTGGCTTCA 
rs852984 tagSNP 
 
GAAAGTTCGGGCACTTTGAG 
GCCATCTTTCTAGTGGTGCAG 
CCAGGGTACATGTGCAGGAT 
rs2398630 uninformative 
 
CAGAGCTGTCGTTTTCTGTGA 
GCTGCAGCTGTGCATTGTAA 
CAGCATCACCACAAACATAAGC 
rs2118727 uninformative 
 
ATAACCTGCCCCATTCACTG 
CCTCCAAGGTTTCTTGAGCA 
GATTTTGTCTCACAGCATCAGCT 
rs2043840 uninformative 
 
CAAAGGGCCAGATATCTCAGAA 
CAAAACAGCGAAGACTGCAA 
CCACCACCTCTGGCATTATCT 
rs6195 tagSNP 
 
GGAAGTTCAGAGTCCCCAGA 
GCAAGCCTCTCATTTTACCG 
TTCCCGTTGGTTCCGAAA 
rs6199 uninformative 
 
GGAAGTTCAGAGTCCCCAGA 
GCAAGCCTCTCATTTTACCG 
CACTTGGGGCAGTGTTACATTACT 
rs6192 uninformative 
 
TCCCATTGAGAGTGAAACTGC 
TCGGATCAGGAAGATAATGTGA 
GCAGCGAAGACTTTTGGTTGAT 
rs6190 uninformative 
 
TCCCATTGAGAGTGAAACTGC 
TCGGATCAGGAAGATAATGTGA 
TTTTATAGAAGTCCATCACATCTCCC 
rs6189 uninformative 
 
TCCCATTGAGAGTGAAACTGC 
TCGGATCAGGAAGATAATGTGA 
GCAGTGTGCTTGCTCAGGA 
 
To remove unincorporated primers and dNTPs, the PCR products were purified 
enzymatically with 1 U of Shrimp Alkaline Phosphatase (SAP) and 5 U of Exonuclease I 
(ExoI) (both from Amersham Biosciences) per 5 µl PCR product. The reaction mixture 
was incubated at +37°C for 15 min, followed by heat inactivation at +80°C for 15 min. 
Approximately 0.01 to 0.1 pmol of the purified PCR product and 2 pmol of an internal 
extension primer that lies just upstream from the polymorphic site were subsequently 
added to 4 µl of MegaBACESNuPe (Amersham Biosciences) genotyping reagent, 
which includes a polymerase enzyme and a mixture of fluorescently labeled ddNTPs. The 
SNuPeTM reaction was performed in a total volume of 10 µl in the following thermal 
cycling conditions: 25 cycles at 96°C for 10 s, 50°C for 5 s, and 60°C for 10 s. The ddNTP 
terminator that is incorporated into the primer is dependent upon the polymorphic 
nucleotide. Excess salts and ddNTPs were removed by Sephadex filtration by using 
Multiscreen filtration plates (Millipore, Bedford, MA, USA) filled with 40 µl of Sephadex 
G-50 Fine DNA grade (Amersham Biosciences) according to the manufacturer’s 
recommendations. The purified primer extension products were separated on a 
MegaBACE 1000 capillary electrophoresis instrument (Molecular Dynamics, Sunnyvale, 
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CA, USA) by using multiple injections. The allele calling was performed by using the 
MegaBACE SNP Profiler software (Molecular Dynamics).  
 
2.3 MassArray MALDI-TOF (I, unpublished results) 
In addition to pooled genotyping, a small set of asthma study samples (see Table 6, 
Materials and Methods, section 1.1) were genotyped with Sequenom’s MassEXTEND 
MassArray chemistry, which utilizes the matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectrometry (Sequenom Inc., San Diego, CA, USA) as a 
detection method (Jurinke 2002). The PCR assays and associated extension reactions were 
designed using the SpectroDESIGNER software (Sequenom Inc.). Primer sequences for 
pooled genotyping are shown in Study I. All amplification reactions were run in the same 
conditions in a total volume of 5 µl with 2.5 ng of genomic DNA (25 ng in pooled 
genotyping), 1 pmol of each amplification primer, 0.2 mM of each dNTP, 2.5 mM MgCl2, 
and 0.2 U of HotStarTaq DNA Polymerase (Qiagen, Chatsworth, CA, USA). Reactions 
were heated at 95°C for 15 min, subjected to 45 cycles of amplification (20 sec at 94°C, 
30 sec at 60°C, 30 sec at 72°C), before a final extension of 7 min at 72°C. Extension 
reactions were conducted in a total volume of 9 µl using 5 pmol of allele-specific 
extension primer and the Mass EXTEND Reagents Kit, before being cleaned using 
SpectroCLEANER (Sequenom Inc.) on a MULTIMEK 96 automated 96-channel robot 
(Beckman Coulter, Fullerton, CA, USA). Clean primer extension products were loaded 
onto 384-groove chips with a nanoliter pipetting system (SpectroCHIP, SpectroJet, 
Sequenom) and analyzed by a MassArray mass spectrometer (Bruker Daltonik GmbH, 
Bremen, Germany). The resulting mass spectra were analyzed for peak identification 
using the SpectroTYPER RT 2.0 software (Sequenom Inc.).  
 
2.4 Genotyping of insertion/deletion polymorphism (III) 
The ACE I/D polymorphism was determined in the Helsinki Birth Cohort Study sample 
set, using PCR technique. The region of interest was amplified using the forward primer 
5’-CTCCCATCCTTTCTCCCATT-3’ and the reverse primer 5’-
GGCGAAACCACATAAAAGTGA-3’. The 5’ end of the forward primer was labeled 
with HEX fluorescent dye. PCR assays were performed in a total volume of 5 µl, 
containing 20 ng human genomic DNA, 250 µM of each dNTP (Amersham Biosciences), 
3.0 mM MgCl2, 1xPCR-buffer, 0.2 units Ampli-Taq Gold DNA-polymerase (all from 
Applied Biosystems), and 0.1 mM of each primer (Sigma-Genosys). The thermal cycling 
conditions were 95°C for 10 min, 30 cycles at 95°C for 30 s, 60°C for 30 s, and 72°C for 
30 s, followed by a final extension at 72°C for 7 min. PCR products were separated using 
the ABI PRISM 377 (Applied Biosystems) DNA sequencer and the data was analyzed 
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using the Genescan 3.1 and Genotyper 2.5 software (Applied Biosystems). The I/D alleles 
were discriminated from each other based on the sizes of the amplified allelic fragments, 
which were either 353 bp or 65 bp.  
 
 
3 POOLED GENOTYPING (I) 
 
3.1 Pool construction 
Three separate DNA pools in triplicate (giving 9 pools altogether) were prepared using 
samples from 30 patients with congenital chloride diarrhea (CLD), 30 carrier parents, and 
30 randomly selected healthy Finnish blood donors from the previous studies on positional 
cloning of the CLD gene (Kere et al. 1993, Höglund et al.1995, Höglund et al. 1996). 
Samples from the Finnish cohort of the “Generale” study were combined in 8-16 pools of 
20, 40, 80, and 160 individual earlier genotyped DNA samples, resulting in a total of 64 
different pools. Prior to pooling, the concentration of each sample was adjusted to 10 
ng/µl based on absorbances at 260 nm in UV-light spectroscopy. A pool of 2 to 6 
heterozygotes for each marker was prepared to get a correction value for the unequal 
amplification of alleles. In addition, a set of pools of known allele frequencies were 
prepared for calibration curves by mixing known homozygous samples to get allele 
frequencies of 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 0.9, 0.95, and 0.975 for each marker. 
 
3.2 Pooled genotyping 
To get replicate measurements, each pool was PCR amplified followed by the allelic 
discrimination reaction in triplicate, and each allelic discrimination product was measured 
2-4 times. The CLD pools were genotyped with PCR-RFLP, SNuPeTM, and MassArray 
MALDI-TOF methods as described, whereas pools of “Generale” study samples were 
genotyped only with the PCR-RFLP method.  
 
3.3 Allele frequency assessment 
A correction factor, k, which is the peak height ratio of the two different alleles in 
heterozygous individuals, was used to correct for uneven amplification. The following 
equation was used, in which HA represents the peak height (or peak area in the case of 
MassArray) of the allele A, whereas HB represents that of the allele B: 
  fA= A
A B
H
H kH+
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4 ALLELE SPECIFIC mRNA EXPRESSION (IV) 
 
To measure the relative GR gene haplotype 3 specific mRNA expression level, we used 
RT-PCR and DNA sequencing. DNA samples were screened to find three heterozygous 
individuals for a silent coding SNP that tags haplotype 3 (rs6196). Reverse transcription 
(RT) was performed twice for each of three individual RNA samples, each cDNA sample 
was PCR amplified twice, and each RT-PCR product was sequenced twice, producing a 
total of 8 measurements for each individual RNA sample. Each genomic DNA sample was 
PCR amplified four times, followed by sequencing in duplicate, giving eight 
measurements altogether. The allele peak height ratio of allele C (tags haplotype 3) and 
allele T was measured, and values of genomic DNA were used as a reference value to 
compensate for the unequal signal intensities of C and T nucleotides and unequal 
amplification of the alternative alleles. The C/T allele peak height ratios of genomic DNA 
were compared with cDNA measurements by using linear regression where dummy 
variables for individual samples were used as covariates (SPSS, version 12.0.1). 
 
4.1 RNA extraction 
RNA was extracted from 50-100 mg frozen human thymus tissue by TRIzol (Invitrogen, 
Carlsbad, CA, USA), following the manufacturer’s instructions. Thymus tissue samples 
were obtained from children undergoing cardiac surgery, where partial removal of thymus 
is a standard procedure for better cardiac access. Informed consent was obtained from the 
children’s parents. TRIzol, a mono-phasic solution of phenol and guanidine 
isothiocyanate, maintains the integrity of RNA during tissue homogenization, but disrupts 
cells and dissolves cell components. Chloroform added to the supernatant after 
centrifugation separates the solution into an aqueous phase (includes RNA) and an organic 
phase during the second centrifugation. The RNA is recovered from the aqueous phase by 
precipitating with isopropyl alcohol. Glycogen was added in this stage to function as a 
carrier to the aqueous phase. After washing with 75% ethanol, the extracted RNA was 
further purified using the RNAeasy total RNA isolation kit, followed by DNAse (both 
from Qiagen) treatment to eliminate genomic DNA contamination.  
 
4.2 RT-PCR 
First-strand complementary DNA (cDNA) was synthesized from 0.5 µg of total RNA in a 
25 µl reaction volume by reverse transcription (RT) using random hexamers (Promega, 
Madison, WIS, USA) and M-MLV reverse transcriptase (Promega), following the 
manufacturer’s instructions. A transcript containing rs6196 in exon 9 alpha of the GR gene 
was PCR amplified using 2 µl of cDNA as a template with a forward primer in exon 7 
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(5’–TGAAAACCTTACTGCTTCTCTCTTC-3’) and a reverse primer in exon 9 (5’-
CGACTTTCTTTAAGGCAACCA-3’). This prevented the amplification of any remaining 
genomic DNA because the two introns are too long to be amplified by PCR. Reverse 
transcription was performed twice for each of the three individual RNA samples, each 
cDNA sample was PCR amplified twice, and each RT-PCR product was sequenced twice, 
producing a total of 8 measurements for each individual RNA sample. Genomic DNA of 
the same three individuals was PCR amplified with the forward primer in intron 8 (5’-
TGAGATGTTCCCACTGACCA-3’) and the reverse primer shown above. Each genomic 
DNA sample was PCR amplified four times, followed by sequencing in duplicates, giving 
a total of 8 measurements for each DNA sample. 
 
4.3 Sequencing 
PCR and RT-PCR products were purified, to remove excess primers and nucleotides, by 
adding 2 µl ExoSAPit (Amersham Biosciences) enzyme mixture into 5 µl of PCR product 
and incubating at +37ºC for 60 min, followed by 15 min heat inactivation at +72ºC. 
Purified products were then sequenced at the Biomedicum sequencing unit core facility 
using the forward primers (1.2 µM) Big Dye Terminator (v1.1) kit (Applied Biosystems) 
and ABI Prism 3130 capillary Genetic Analyzer (Applied Biosystems). 
 
 
5 STATISTICAL ANALYSES (I, II ,III, IV) 
 
Genotypes for each marker were confirmed to follow the Hardy-Weinberg equilibrium 
(p2+2pq+q2=1, where p and q denote the allele frequencies). For comparison of discrete 
variables, we used chi-square or Fischer’s exact tests whenever appropriate, and logistic 
regression to correct for confounding in Study II. For continuous variables we used 
Students’ t-test (if two classes), analysis of variance (ANOVA) (if more than two classes), 
and linear regression when several variables were included in the model. These analyses 
were performed using SPSS for Windows statistical software package, version 12.0.1 
(SPSS Inc. Chicago, Illinois, USA). Relative risks in study II were calculated using 
Poisson regression with the program called R (http://www.r-project.org/). Other risk 
estimates in study II including attributable risk (AR), attributable risk proportion (AR%), 
population attributable risk (PAR), and population attributable risk proportion (PAR%) 
were calculated manually using the equations described in study II.  
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RESULTS AND DISCUSSION 
 
 
1 SETTING-UP THE SNP GENOTYPING 
 
1.1 PCR-RFLP 
The workflow of the PCR-RFLP SNP genotyping method that was set up at the Finnish 
Genome Center is described in Figure 5.  
 
 
 Figure 5. SNP genotyping work flow of PCR-RFLP at the Finnish Genome Center. 
 
The method was evaluated by genotyping 14 SNPs from a total of 5,184 individual DNA 
samples. The different sample sets are described in more detail in Table 6 (Materials and 
Methods, section 1.1). Success rates for the individual markers ranged from 91.0% to 
98.9%, with an average success rate of 95.3% for these 14 markers. The missing 
genotypes of the “pregnancy complication” data set were genotyped again, which 
improved the final success rate of this data set on average to 99.5%, indicating that the 
lower success rate was not due to poor sample quality. Assay conversion rate, meaning the 
DNA samples from 96-well plate format into 384-well PCR plates 
with Hydra pipetting station (Robbins). DNA samples
PCR PCR reagents distributed with Tecan robot (Tecan). Thermal cycling 
performed on a GeneAmp PCR system 9700 (Applied Biosystems).
Restriction enzyme 
cleavage
Restriction enzyme mixture distributed with Hydra pipetting station; 
incubation at +37ºC or 60 ºC for 3 h/over night depending on 
enzyme. 
Pooling of PCR 
products
Up to 9 markers within a sample pooled together with Hydra 
pipetting station.
Gel electrophoresis Fragment separation by ABI PRISM 377 sequencer (Applied 
Biosystems).
Genotypes assessed with Genescan 3.1 and Genotyper 2.5 software 
(Applied Biosystems).Allele calling
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proportion of successful assays compared to attempted assays, was 87.5% (14 successful 
assays out of 16 attempted). The assay conversion rate was actually higher than expected, 
as not every SNP changes a restriction site for a known restriction enzyme. The creation of 
artificial restriction sites by using modified sequences in PCR primers obviously increased 
the assay conversion rate.  
 
The error rate (i.e. the frequency of wrong genotypes) was not systematically determined 
in large scale, but it is estimated to be very low. This presumption is based on the 
following observations: Positive findings of FVL and FII G20210A polymorphisms (97 
genotypes) were checked with Light Cycler® instrument (Study II) at the Finnish Red 
Cross Blood Transfusion Center, and all genotypes were concordant. In addition, sporadic 
re-genotypings showed that there were no disconcordant genotypes. The error rate is 
therefore estimated to be below 0.1%. The error rate would have been slightly higher 
without manual checking of the automated genotype calls. Gel based electrophoresis is 
prone to errors because, for example, of manual loading and because the samples are 
loaded on the gel without any physical barrier. Occasionally, adjacent lanes were 
overlapped, which would automatically lead to misinterpretations if genotypes were not 
manually checked. These error sources could have been avoided if capillary 
electrophoresis instrument had been used. Poor spectral separation appeared to be only a 
minor problem, and usually in situations in which the amount of fluorescently labeled 
product was too high. The incomplete digestion of a PCR product was not causing 
genotyping errors in our assays, because they were automatically caught up by the use of 
an additional control restriction site. However, the incomplete digestion was the most 
common reason for discarding the genotype. The resulting lower success rate is obviously 
much more acceptable than incorrect genotypes; therefore the use of RFLP in large scale 
genotyping without an additional restriction site cannot be recommended. Figure 6 shows 
examples of signal peaks obtained after the complete digestion. 
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Figure 6. Signal peaks obtained from the Genotyper 2.5 software (Applied Biosystems) 
after gel electrophoresis on ABI 377. Four different markers from the pregnancy 
complications study (II) are shown. The x-axis represents the fragment size in base pairs 
and the y-axis the signal intensity of the peak. The size of each fragment and the height of 
signal intensity are shown in the labels below each individual allele peak, respectively.  
 
A low level of multiplexing is also possible with PCR-RFLP; here the reactions were 
multiplexed by two. Even the fragments that are to be cleaved by different restriction 
enzymes can be pooled together if the required conditions are similar and there are no 
restriction sites for the second enzyme. The sizes of the fragments can be defined precisely 
with automated sequencers. Therefore, any spurious fragment sizes are easily detected. 
After the PCR assay followed by the enzymatic cleavage, a maximum of 9 markers were 
pooled together and analyzed in the same lane. This was possible due to the four different 
fluorescent dyes (FAM-6, HEX, NED, and ROX for the size standard) included in the 
PCR product by incorporation in the oligonucleotide primers, and careful design of the 
fragment sizes that were pooled together. Assay design in PCR-RFLP is laborious, 
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especially if restriction sites have to be created by modifying the primer sequences, in case 
of absence of a natural digestion site. Obviously, a computer program could be developed 
for this purpose.  
 
1.2 SNuPeTM 
The SNuPeTM genotyping workflow that was set up is described in Figure 7.  
 
 
Figure 7. SNP genotyping work flow of SNuPeTM at the Finnish Genome Center. 
 
In total, 1,417 samples were genotyped by using the SNuPeTM technique with varying sets 
of SNPs (see Table 6, Materials and Methods, section 1.1), yielding approximately 25,000 
genotypes. The success rates for the genotyped SNPs ranged from 79.1% to 98.9%, the 
average of the genotyping reactions being 95.1%. The assay conversion rate was 84.2% 
(117 successful assays of 139 attempted), which was surprisingly lower than that observed 
for PCR-RFLP (87.5%). However, the number of markers in PCR-RFLP was much lower 
(16 attempted assays) than with SNuPeTM. The most common cause for failed assays in 
DNA samples from 96-well plate format into 384-well PCR plates 
with Hydra pipetting station (Robbins). DNA samples
PCR PCR reagents distributed with Tecan robot (Tecan). Thermal cycling 
performed on a GeneAmp PCR system 9700 (Applied Biosystems).
Enzymatic purification
(ExoI + SAP)
Enzyme mixture distributed with Hydra pipetting station. Incubation 
at +37ºC followed by heat inactivation at +80ºC. Exonuclease I 
(ExoI) and Shrimp Alkaline Phosphatase (SAP) degrade 
unincorporated primers and dNTPs.
Single base Extension
(SBE)
Primer extension mixture distributed with Hydra pipetting station.
Thermal cycling performed on a GeneAmp PCR system 9700 
(Applied Biosystems).
Sephadex purification Excess salts and ddNTPs removed by Sephadex filtration using 
Multiscreen filtration plates (Millipore).
Capillary 
electrophoresis
Primer extension products separated on a MegaBACE 1000 capillary
electrophoresis instrumet (Molecular Dynamics). Multiple injections 
allow up to 12 SNPs to be separated on a same capillary.
Allele calling Genotypes assessed with the MegaBACE SNP Profiler software (Molecular Dynamics).
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SNuPeTM, and in fact in all primer extension based methods, was related to the limited 
possible positions for the primer extension oligonucleotide, which has to anneal just 
upstream of the SNP site. The assay design is thus very sequence dependent. A typical 
failure for the assay was the presence of an additional signal peak, also in the negative 
control, which disturbed the interpretation of the allele peaks. Extension products need to 
be carefully purified either enzymatically with Shrimp alkaline phosphatase treatment 
(SAP) followed by dialysis for salt removal, or with Sephadex filtration, as we decided to 
do, to avoid the appearance of these extra signal peaks. Another possible reason for these 
signals in negative water controls may be the incomplete synthesis of the oligonucleotides 
(HPLC purified primers are recommended) or primer-dimer formations. Again, the 
genotyping errors were not scrutinized systematically in large scale. However, a 
genotyping of sporadic replicates found no disconcordancies, suggesting very low error 
rates. Figure 8 shows an example of the electropherogram from the SNPProfiler software, 
after the SNuPeTM reactions and MegaBACE capillary electrophoresis run with multiple 
injections. 
 
 
Figure 8. Examples of the SNPProfiler image of the allele peaks; CA heterozygote (upper 
left), A homozygote (lower left), T homozygote (upper right), and CT heterozygote (lower 
right). Injection markers (shown in black) separate the SNPs in the same capillary.  
 
1.3 Comparison of the used SNP genotyping techniques 
The two evaluated SNP genotyping techniques seem to perform equally well when the 
success rates or assay conversion rates are compared (see Table 9). The SNuPeTM 
technique has a three-fold throughput compared to PCR-RFLP, making it a slightly more 
attractive technique. On the other hand, PCR-RFLP can be used in every laboratory that 
has an automated sequencer of any kind, whereas SNuPeTM requires the MegaBACE 
capillary electrophoresis instrument, mainly because of the multiple injections feature. The 
multiplexing cannot be easily achieved: PCR assays in PCR-RFLP were routinely 
multiplexed by two, but the SNuPeTM cannot be multiplexed if the SNPProfiler software is 
used. Mainly for this reason, these techniques cannot achieve a high-throughput capacity. 
For comparison, a small genotyping project with the Asthma study samples (see Table 6, 
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Materials and Methods, section 1.1), genotyped using MassArray MALDI-TOF, is 
included in Table 9. Figure 9 illustrates the feasible sizes of projects for some of the 
selected genotyping platforms. 
 
Table 9. The properties of the used SNP genotyping platforms, and a summary of the 
conducted genotyping. 
 PCR-RFLP SNuPeTM MassArray 
MALDI-TOF 
Theoretical throughput ~ 1,500 genotypes /day ~ 4,500 genotypes /day ~ 100,000 
genotypes /day 
Number of produced 
genotypes 
34,842 25,819 5,109 
Number of SNPs 14 117 15 
Success rate % (range) 95.3 % (91.0-98.9%) 95.1% (79.1-98.9%) 94.6% (83.1-100%) 
Assay conversion rate % 87.5% 84.2% 78.9% 
Advantages No need for specialized 
instrument 
 
Protocol is fairly simple 
Easy assay design and 
data analysis 
 
 
Automated assay 
design, workflow 
and data collection 
  
Multiplexing 
capacity 
Disadvantages Expensive fluorescent 
primers 
 
Difficult assay design 
 
Not suitable for every 
SNP 
 
Not suitable for high 
throughput 
Expensive 
consumables 
  
Extensive post-PCR 
processing 
 
Not suitable for high 
throughput 
Expensive 
instruments and 
consumables  
 
Extensive post-PCR 
processing 
 
 
Figure 9. The feasible number of samples and SNPs for genotyping platforms that were 
used in this thesis (PCR-RFLP, SNuPeTM, MassArray MALDI-TOF), and for the high-
throughput techniques by Affymetrix and Illumina.  
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Recently, Lahermo and co-workers (2006) published a quality assessment survey of six 
Swedish, three Finnish, one Norwegian, and one Estonian SNP genotyping laboratories. 
Four of the laboratories used allele-specific oligonucleotide hybridization as a genotyping 
method, whereas the majority (7 laboratories) used primer extension based methods. The 
test laboratories genotyped 18 or 6 SNPs on 47 DNA samples that were blinded for 
genotypes. The assay conversion rates varied from 83.3% to 100% between different 
laboratories, whereas the range of the success rates for a SNP was from 95.0% to 100% 
(when the assays that gave a success rate of 0% were discarded). The performance of 
PCR-RFLP and SNuPeTM (when throughput is not considered) in our hands was exactly in 
the same range. When two poor quality DNA samples were also included in the study by 
Lahermo and co-workers (2006), the mean accuracy per SNP varied from 98.9% to 100%, 
six out of the twelve genotyping platforms having no genotyping errors. The average 
accuracy per SNP of all laboratories was 99.7%, which suggested that modern SNP 
genotyping techniques are very reliable. 
 
An ideal SNP genotyping platform would offer high-throughput capacity, affordable price, 
simple assay design, accurate and reliable results, it should be robust, and both the 
laboratory procedure and genotype calling should be easily automated (Syvänen 2001, 
Kwok 2001, Tsuchihashi and Dracopoli 2002, Chen and Sullivan 2003, Twyman and 
Primrose 2003). Of the evaluated methods, PCR-RFLP and SNuPeTM do not reach a high-
throughput capacity. The genotyping cost remains quite high because of the low level of 
multiplexing capability. In addition, the sample design is quite laborious for the PCR-
RFLP. On the other hand, the other requirements listed above are fulfilled with these 
platforms; genotyping results are accurate and reliable, methods perform robustly, and 
genotyping procedures can be, at least to some extent, easily automated. When choosing 
the genotyping platform, requirements for applications should be carefully considered. 
Some of the techniques suit better for the projects with a large number of samples but low 
number of SNPs (e.g. TaqMan), whereas others, such as micro array based techniques, 
function vice versa (suits for the projects with large number of SNPs but low number of 
samples) (Chen and Sullivan 2003). SNuPeTM is quite flexible in this regard, but PCR-
RFLP suits best for the projects with a small number of markers because of the complex 
assay design and expensive fluorescently labeled oligonucleotide primers. In addition to 
accuracy and throughput, cost structure is an important criteria for the selection of the 
genotyping method. It consists of costs for instrument, genotyping set-up, labor, fixed cost 
per marker, and consumable costs proportional to the amount of usage (Chen and Sullivan 
2003). Instrumentation costs are typically high for most technologies, but in the case of 
PCR-RFLP and SNuPeTM, it cannot be considered very expensive since the two 
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sequencers were already in use for microsatellite genotyping and sequencing. Thus, the 
flexibility of the genotyping platform, in the form of multiple applications, reduces the 
proportional instrumentation cost. If the fixed cost per SNP is high, as in the case of PCR-
RFLP, the efficient way to decrease the expenses per genotype is to increase sample size 
so that fixed primer costs can be shared by many samples. SNuPeTM on the other hand, 
and other primer extension based techniques, belong to the group of platforms in which 
the genotyping costs are proportional to the amount of consumables used. Labor expenses 
are reduced if the genotyping procedure can be automated (Chen and Sullivan 2003). 
 
As listed in the study by Lahermo and co-workers (2006), there are important aspects to be 
remembered when performing large-scale genotyping; 1) As it is known that genotyping 
error can be very harmful especially in association studies of complex diseases, 
genotyping errors should be avoided even if it means lower success rate; 2) The quality of 
DNA should be always monitored, since bad quality DNA is more prone to give spurious 
genotyping results; 3) A careful assay design is crucial, because SNPs in repetitive 
sequences and primer- or probe-binding sites tend to disturb the genotyping reaction and 
may lead to error.  
 
 
2 POOLED GENOTYPING (I) 
 
To save effort in large genetic association studies, the performance of different genotyping 
platforms in pooled genotyping was evaluated. All three tested genotyping techniques, 
PCR-RFLP, SNuPeTM, and MassArray MALDI-TOF proved to be accurate for allele 
frequency estimations from pooled DNA samples. MassArray MALDI-TOF was used 
mainly as a reference method, as its performance in this application has been shown to be 
good (Le Hellard et al. 2002, Mohlke et al. 2002, Herbon et al. 2003). The actual allele 
frequencies of DNA pools consisting of 30 samples of congenital chloride diarrhea (CLD) 
patients, 30 carriers, and 30 controls were not known. Instead of comparing the estimated 
allele frequencies to actual allele frequencies, we tested whether there were significant 
allele frequency differences between these three different pools, and whether we could 
have narrowed down the genomic region associated to CLD by using a pooled genotyping 
approach. Indeed, we saw strong associations between CLD and markers closest to the 
SLC26A3 gene, in which the genetic defects are known to cause this autosomal recessive 
disease (Höglund et al. 1995, 1996). When the estimated allele frequencies from all the 
three genotyping platforms were combined, the allele frequency differences between the 
patient and control pools for the SNPs surrounding the target gene were 50.5% 
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(p=1.56x10-16) and 50.0% (p=4.34x10-12) for the SNPs rs1018869 (0.31 Mb from the 
target gene) and rs764113 (1.27 Mb from the target gene), respectively. Estimated allele 
frequencies obtained from each genotyping platform of all tested SNPs are shown in Table 
3 in Study I (page 412).  
 
A correction factor (based on allele peak height ratios obtained from heterozygous 
individuals) was always used to correct for the uneven signal peak heights of the 
alternative alleles. In addition to uneven amplification during PCR or uneven primer 
extension, the uneven signal intensities of different fluorescent labels in SNuPeTM and 
differential mass of the various dNTPs and ddNTPs in MassArray will result in uneven 
allele peak signal intensities. In the PCR-RFLP method, only uneven amplification during 
PCR causes uneven allele peak signal intensities, because only fully cleaved fragments are 
accepted. The average heterozygous ratio among all SNP assays was 1.44 (range 1.00 to 
2.15) in RFLP, 2.02 (range 1.08 to 3.95) in SNuPeTM, and 1.70 (range 1.05 to 3.47) in 
MassArray. This is in good agreement with a study of 101 SNPs in SNaPshot assays, 
which showed the average heterozygote ratio of 2.13, ranging from 1.03 to 5.33 (Norton et 
al. 2004). In our experience, these heterozygous ratios should be measured in parallel, at 
the same time as the pools under evaluation, because the reaction conditions seem to affect 
the allelic ratio. This issue has not been considered in most of the studies using pooled 
genotyping.  
 
Calibration plots for each marker were prepared to evaluate the sensitivity of the method 
and to test whether the same correction factor can be used in the whole range of allele 
frequencies. The calibration plots proved to be linear for each marker, justifying the use of 
one correction factor for each SNP. However, the accuracy suffered in the extreme ends of 
the calibration plots, showing that the assessment of minor allele frequencies of 5% or less 
in pooled genotyping may not be reliable, and cannot be recommended. This is in 
accordance with other genotyping techniques that have been used in pooled genotyping 
(Germer et al. 2000, Ross et al. 2000, Barratt et al. 2002). The performance in extreme 
ends also varied depending on the SNP assay. Examples of the electropherograms from 
SNPProfiler software after pooled genotyping are shown in Figures 10 and 11, with Figure 
10 representing the measurements for the calibration plot and Figure 11 showing the 
differential peak height ratios of different pools. 
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Figure 10. Example of the calibration plot for the SNP rs734787 used in SNuPeTM. A) 
Electropherogram of different allele frequency combinations. As shown by the pool 8 
(allele frequency of 0.9) and pool 2 (allele frequency of 0.05), the other extreme end of the 
allele frequency can be more sensitive than the other. B) Measured value and the fitted 
value for a calibration plot.  
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Figure 11. Example of allele peaks obtained from the SNPProfiler software (SNuPeTM) 
from CLD patient, carrier, and control pools, genotyped with the markers rs1018869 
(upper) and rs764113 (lower).  
 
The most error prone step in pooled genotyping was shown to be the volumetric error in 
constructing the DNA pools, as shown by the higher SD between the estimated allele 
frequencies of three replicate pools compared to the SD between adjacent PCR, allele 
discrimination reactions, or allele detection steps (Table 10). DNA-pool formation is also 
the most time-consuming and labor intensive step of the whole process, at least if the 
number of pooled DNAs is very large. Probably for this reason, many of the studies using 
pooled genotyping have not constructed replicate pools, although replicate PCR and allelic 
discrimination measurements are routinely conducted. We measured the DNA 
concentrations only based upon UV absorption. However, it has been recommended that 
after the crude estimation of DNA content with UV absorption, a more precise method 
such as fluorimetric quantitation based on the binding of PicoGreen to double stranded 
DNA, should be used for the accurate determination of concentrations (Sham et al. 2002, 
Norton et al. 2004).  
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Table 10. Sources of errors during different steps of genotyping and pooling strategy 
(modified from I). 
Error RFLP (SD) SNuPeTM 
(SD) 
MALDI-TOF (SD) Combined (SD) 
Between tested methods - - - 0.0301 
 
Between assaysa   0.0342 0.0356 0.0259 0.0319 
 
Between assaysb  
 
0.0224 0.0260 0.0166 0.0217 
Volumetric error 0.0247 0.0277 0.0263 0.0262 
 
Amplification error 0.0204 0.0190 0.0127 0.0174 
 
Detection errorc 
 
0.0117 0.0069 0.0129 0.0105 
a Pool construction considered 
b Pool construction not considered 
c Between lane, injection or chip/spot 
 
In a second part of the study, we further evaluated the performance of the PCR-RFLP in 
pooled genotyping, using the Generale study samples, for which the genotypes were 
known. This was done mainly because this traditional technique is very commonly used 
for individual genotyping in laboratories that are not specialized in high-throughput 
genotyping. The PCR-RFLP method has been criticized for being unreliable in pooled 
genotyping due to the possible incomplete enzymatic cleavage (Sham et al. 2002). 
However, because we are using an additional restriction site as a control of cleavage, the 
performance of the PCR-RFLP was shown to be as reliable as other tested methods, the 
SDs between measurements being 0.022, 0.026, and 0.017 for the RFLP, SNuPeTM, and 
MassArray MALDI-TOF, respectively (the pool construction is not considered in these 
values). This competes well with the SD values (varying from 0.02 to 0.04) shown by the 
other studies (reviewed in Sham et al. 2002). In the further evaluation of the PCR-RFLP 
method we did not prepare replicate pools of the same individuals. Instead, we divided 
samples in several (8 or 16) different individual pools of 20, 40, 80, and 160 individuals. 
This decreases the volumetric error in a similar way to the use of replicate pools, but keeps 
the amount of pipetting to a minimum. Barratt and co-workers estimated that the most 
cost-efficient way to perform pooled genotyping without sacrificing accuracy, would be 
single formation and analysis of several small pools of ~50 individuals, instead of 
replicate formation and measurement of large pools (Barratt et al. 2002). The average 
difference of the estimated allele frequency from the actual allele frequencies varied from 
0.9% to 6.5% in PCR-RFLP, depending on the SNP. This shows that some of the SNPs 
suit extremely well for pooled genotyping, while others may have to be discarded because 
of their poor performance. SNPs that do not have constant allele peak height ratios in 
heterozygous samples should not be used.  
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A typical feature of the DNA pooling method is that the benefits of the method improve as 
the number of samples pooled together increases (Le Hellard et al. 2002). Therefore, our 
study of 30 individuals in each of the patient, carrier, and control pools functions only as 
an evaluation of the genotyping methods in pooled genotyping; more samples should be 
pooled together to get the full benefit. Le Hellard and co-workers observed that the 
number of samples in the pool does not have considerable effect on the accuracy (Le 
Hellard et al. 2002); therefore it is more economical to genotype large pools. The pooled 
genotyping approach is most accurate for the relatively common alleles, since most of the 
SNPs function appropriately at the range of more than 10% minor allele frequency. 
Although the approach seems to suit well for traditional case-control studies, it is difficult 
to apply if any kind of stratification based on environmental factors is needed. The 
haplotypes cannot be easily inferred from pooled samples and the allele frequency 
estimation does not seem to be accurate in the extreme ends of the allele frequencies 
(<5%). Therefore, we chose to continue with individual genotyping in the following 
association studies, which also take the environmental factors into account. 
 
 
3 ASSOCIATION STUDIES 
 
3.1 Genetic factors in pregnancy-associated venous thrombosis (II) 
Of the 100,000 consecutive pregnancies in Finland during the years 1997 and 1998, 34 
objectively verified deep venous thrombosis cases during the pregnancy or puerperium 
were observed. Factor V Leiden (FVL), but not the other six tested polymorphisms, 
associated strongly with pregnancy-related deep venous thrombosis (OR 11.6; 95% CI 
3.6-33.6). This is in accordance with other studies of pregnancy related DVT showing 
similar odds ratios (4.5-16.3) for FVL (McColl et al. 2000, Grandone et al. 1998). The 
number of DVT patients proved to be too small to rule out the possible association of 
some other polymorphisms, especially the prothrombin (FII G20210A) mutation as shown 
by the power calculations in Table 11.  
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 73 
Table 11. Association of tested polymorphisms with pregnancy-associated deep venous 
thrombosis, and power calculations (modified from II). 
Polymorphism Cases, n=34 
(MAF %) 
Controls, n=641 
(MAF %)  
P OR (95%CI) Lowest 
detectable OR 
FV Leiden 11.8 1.1 3.07x10-5 11.6 (3.6-33.6) 7.6 
FII G20210A 1.5 0.5 0.3 3.2 (0.07-27.6) 14.0 
FV R2 (His1299Arg) 12.1 9.9 0.6 1.3     (0.5-3.2) 3.0 
MTHFR Ala223Val 22.1 24.3 1.0 0.9     (0.4-1.9) 2.9 
FXIII Val34Leu  19.7 19.0 0.7 1.2     (0.4-1.9) 0.2* 
PROC Trp380Gly 0 0 N.A. N.A. N.A. 
TFPI Pro151Leu 0 0.08 N.A. N.A. N.A. 
*FXIII Val34Leu has been proposed to be protective against venous thrombosis. 
Of the previously reported environmental factors contributing to pregnancy-associated 
venous thrombosis, such as high BMI, advanced age, non-O blood group, smoking, high 
parity, multiple pregnancy, and cesarean section (Walker 2003, Larsen et al. 2005), high 
BMI (>30) and advanced age (>35 years) were independently associated with a higher 
incidence of DVT and interacted with FVL, raising the ORs to as high as 93.8 (95% CI 
9.2-955.3) for BMI and 43.7 (95% CI 6.6-287.4) for age if combined with FVL carrier 
status. In addition, non-O blood group, although not independently associated with DVT, 
increased the risk of DVT if combined with FVL (OR 25.1; 95% CI 6.6-95.4). The mode 
of interaction of FVL with age was additive, whereas with BMI and non-O blood group it 
seemed to be multiplicative. 
 
Although the impact of FVL on pregnancy-related DVT has been widely studied (McColl 
et al. 1997, Grandone et al. 1998, Gerhardt et al. 2000, Martinelli et al. 2002), the risk 
estimates at the population level have been missing. Owing to our study design, we were 
able to estimate measures for the absolute risk, attributable risk (AR), attributable risk 
proportion (AR%), population attributable risk (PAR), and population attributable risk 
proportion (PAR%) for FVL by its own, and stratified to different classes of BMI, age, 
and blood group, as shown in Table 12. Among FVL carriers, 92% of the thromboses were 
estimated to be caused by this polymorphism (AR%). At the population level (among 
100,000 pregnant women), FVL was responsible for 19% of thromboses (PAR%). 
Although the impact of FVL on venous thromboses at the individual level is considerable, 
due to its low prevalence in the population, the population attributable risk for age over 35 
years (23%), BMI over 25 (33%), and non-O blood group (35%) were higher than that for 
FVL. 
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Table 12. Estimated absolute and attributable risks of FVL for deep venous thrombosis in 
the cohort of 100,000 pregnancies (modified from II). 
 
 
 
Absolute risk 
per 100,000 
FVL carriers 
Absolute risk per 
100,000 FVL 
non-carriers 
RR (95%CI) AR% (95%CI) PAR% 
(95%CI) 
All   318  28   11.5 (5.0-26.5) 92 (80-96) 19 (16-20) 
Age      
<25   322     10 32.8 (3.0-361.5) 97 (66-100) 32 (22-33) 
25-35   213     27   7.8 (1.8-33.7) 87 (45-97)   9 (4-10) 
>35   426     62   6.9 (2.0-23.4) 85 (50-96) 31 (18-35) 
BMI      
<25   116   21   5.7 (1.3-24.8) 82 (23-96) 10 (3-11) 
25-30   623     38 16.5 (3.4-79.6) 94 (71-99) 21 (16-22) 
 >30 1936     83 23.4 (5.6-97.9) 96 (82-99) 36 (31-37) 
Blood group      
O   108 19   5.6 (0.7-46.4) 82 (-49-98) 12 (-7-14) 
 non-O   464 31 14.8 (6.0-36.6) 93 (83-97) 21 (18-22) 
 
The role of FVL is well-established in thrombophilia (Bertina et al. 1994, Lane et al. 1996, 
Martinelli et al. 2000), which is affected by both environmental and genetic factors. 
Therefore, FVL is a good example of a susceptibility gene for a complex multifactorial 
disease. However, the relative risk of this polymorphism is much larger than usually 
anticipated for a complex disease-predisposing polymorphism. Although the allele 
frequency of FVL is quite low (1.2% in Finnish population), combined with other risk 
factors, such as pregnancy in our study, its effect at the population level is quite 
remarkable (population attributable risk proportion being 19%). The number of women 
with DVT among 100,000 consecutive pregnancies was too small to detect the interaction 
between other polymorphisms. The FVL and prothrombin (FII G20210A) polymorphisms 
have been shown to interact with each other, although these double carriers are very rare 
(van Boven et al.1999). 
 
3.2 Genetic factors modifying the link between small birth size and type 2 
diabetes related phenotypes (III and IV) 
3.2.1 Angiotensin-converting enzyme insertion/deletion polymorphism (III) 
We examined interactions between the ACE gene I/D polymorphism and the size at birth 
on glucose and insulin metabolism among 423 elderly (aged around 70 years) individuals. 
In our study population, the frequencies for the insertion and deletion alleles were 41.1% 
and 58.9%, respectively. This is in accordance with other reported prevalence of ACE I/D 
polymorphism in Finland (Fuentes et al. 2002, Viitanen et al. 2001). The genotypes 
followed the Hardy-Weinberg equilibrium; therefore there is no reason to believe that 
heterozygotes would have been missed, as suggested by Shanmugam and co-workers 
(1993), who criticized the use of only PCR for genotyping the ACE ins/del polymorphism. 
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The allele peak height (signal intensity) for the deletion allele was several fold lower than 
that for the insertion allele. Therefore, it was important not to accept allele calls with low 
signal intensities.  
  
In a standard oral glucose tolerance test, the presence of the I allele was weakly associated 
with higher indices of insulin secretion (insulin at 30 min and insulin area under the curve 
(AUC), a marker of total insulin secretion) and lower glucose at 120 min, as shown in 
Table 13. No association was seen between ACE genotype and blood pressure. ACE has 
been proposed to be a good candidate gene for blood pressure regulation, but the 
association between ACE I/D polymorphism and hypertension have been conflicting 
(O’Donnell et al. 1998), with the majority of reported association studies being negative 
(Berge and Berg 1994, Johnson et al. 1996, Islam et al. 2006). In addition, no association 
was seen between ACE I/D polymorphism and insulin resistance, i.e. the diminished 
ability of cells to respond to insulin, which was expressed as the homeostasis model 
assessment (HOMA) for insulin resistance index (fasting glucose [mmol/L] x fasting 
insulin [µU/mL]/22.5) (Matthews et al. 1985). 
 
Table 13. Results of the oral glucose tolerance test with calculated indices of insulin 
secretion and insulin resistance, in relation to the ACE I/D genotype (modified from III). 
 ACE genotype  
 II ID  DD p for trend*  
Number of subjects 69 210 144  
Current BMI (kg/m2) 27.2 27.4 27.3 0.8 
Oral glucose tolerance test     
    Glucose at baseline (mmol/l) 5.5 5.5 5.5 0.7 
    Glucose at 30 min (mmol/l) 9.2 9.3 9.5 0.3 
    Glucose at 120 min (mmol/l) 7.1 7.6 8.0 0.03 
    Insulin at baseline (pmol/l) 72 64 65 0.3 
    Insulin at 30 min (pmol/l) 530 463 443 0.04 
    Insulin at 120 min (pmol/l) 532 494 482 0.3 
HOMA insulin resistance index 2.52 2.29 2.29 0.3 
Insulin AUC (pmol/l) 414 372 359 0.06 
Impaired glucose tolerance (%) 28 30 29 0.3 
Type 2 diabetes (%) 13 15 19 0.2 
* p values are adjusted for sex, current age, and BMI. 
All birth related measurements were significantly higher in individuals who were 
homozygous for the ACE insertion allele (II), followed by heterozygous individuals (ID), 
and thereafter individuals homozygous for the deletion allele (DD), suggesting an allele 
dosage effect (Table 14). In addition, the mean gestational age was significantly lower 
among II individuals. 
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Table 14. Birth measurements adjusted for gestational age and sex (means) according to 
ACE genotype (modified from III). 
 ACE genotype  
 II ID  DD p for trend 
Birth weight (g) 3441 3364 3285 0.008 
Length at birth (cm) 50.2 49.9 49.7 0.02 
Ponderal index (kg/m3)* 27.2 26.9 26.7 0.1 
Head circumference (cm) 34.9 34.5 34.4 0.007 
Gestational age (days) 272 276 278 0.006 
* A measure of thinness at birth calculated as weight/ length3 
 
Interestingly, the relationship between the ACE genotype and the indices of insulin 
secretion in adulthood was dependent on size at birth. As shown in Table 15, the 
association between the insertion allele and the higher insulin at 30 min and insulin AUC, 
as well as the lower glucose at 120 min, are seen only within subjects with birth weight in 
the lowest third. Likewise, low birth weight was associated with higher indices of insulin 
secretion among individuals with II and ID genotype but not among those with DD 
genotype.  
 
Table 15. Indices of insulin secretion and glucose tolerance according to ACE I/D 
genotype and birth weight (modified from III).  
 ACE genotype  
Birth weight  II ID  DD p for trend 
 Insulin at 30 min (pmol/l)  
Lowest third  654 (22) 560 (63) 423 (56) 0.0004 
Middle third  585 (19) 467 (73) 451 (49) 0.1 
Highest third  423 (28) 402 (74) 471 (39) 0.3 
p for trend 0.003 0.003 0.6  
p for interaction 
 0.003   
 Insulin AUC (pmol/l)  
Lowest third  470 449 356 0.008 
Middle third  453 375 368 0.2 
Highest third  362 325 365 0.7 
p for trend 0.01 0.001 0.6  
p for interaction 
 0.05   
 Glucose at 120 min (mmol/l)  
Lowest third  7.1 7.7 8.4 0.03 
Middle third  7.1 7.9 8.5 0.07 
Highest third  7.4 7.4 7.1 0.6 
p for trend 0.5 0.6 0.07  
p for interaction  0.07   
Numbers are geometric means, with numbers of cases in parenthesis. Glucose and insulin concentrations are 
adjusted for sex, current age, and BMI, whereas birth weight is adjusted for gestational age and sex.  
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These findings are consistent with a previous study, which showed that the I allele was 
associated with a greater insulin response among a group of young adults born extremely 
small for gestational age (Cambien et al. 1998). We have now shown this association in 
elderly people whose birth weights were in the normal range. Although insulin resistance 
is commonly associated with a low birth size (Phillips 1996, Lithell et al. 1996, Eriksson 
et al. 2002b), our results presumably do not indicate insulin resistance. This is because 
similar relationships with fasting insulin concentration or HOMA for insulin resistance 
index, commonly used indicators of insulin resistance, were not detected. Furthermore, 
glucose values (at 120 min) were significantly higher among individuals with the DD 
genotype. Individuals with insulin resistance have typically high levels of both blood 
glucose and insulin at the same time (Ganong 2005b). The I allele has shown to be 
protective against complications of diabetes (Ruiz et al. 1994, Huang et al. 1998, Kennon 
et al. 1999), which further supports the assumption that our results do not indicate insulin 
resistance. Although little is known about the effects of the renin-angiotensin system on 
beta cells, it is possible that a small body size at birth is associated with insulin resistance, 
while the I allele confers an increased capacity of the pancreatic beta cells to respond to 
the increased insulin demand.  
 
3.2.2 Glucocorticoid receptor gene haplotype (IV) 
In 437 elderly subjects born between 1924-1933 in Helsinki, we studied whether the type 
2 diabetes or related phenotypes are predicted by either the body size at birth, haplotypes 
of the glucocorticoid receptor (GR) gene locus, or both. The phenotypes of interest 
included the presence of impaired glucose tolerance or type 2 diabetes, glucose and insulin 
concentrations during the oral glucose tolerance test, fasting plasma total and free cortisol 
concentrations, and more detailed evaluation results of the HPAA function in a subset of 
162 women.  
 
As assessed from the HapMap data using the Haploview software, the GR gene seems to 
locate within a single LD block (Figure 12).  
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Figure 12. Exon/intron and LD Structure (CEU; HapMap data release #19) of the GR 
locus on chromosome 5q31. Genotyped SNPs are shown by the rs numbers. Light gray 
boxes represent untranslated exons (exon 1 and part of exon 9α). Multiple alternative first 
exons known to exist are not shown. Also 9α and 9β are alternative exons, 9α being the 
transcriptionally active form (modified from IV). 
  
We were able to cover most of the common variation in the GR gene with five 
polymorphic SNPs, which were located within a single LD block. As a result of the tight 
LD block, four common haplotypes covered 96.5% of the observed haplotypes. The allele 
frequencies corresponded well with those shown by the HapMap data and the study by 
Stevens and co-workers who have also studied the haplotype structure of the GR gene 
(Stevens et al. 2004) (see Figure 13). 
 
Haplotype 3, a common haplotype with a frequency of 20.8%, directly associated with 
lower weight (p=0.02) and length (p=0.01) at birth, and higher fasting plasma (p=0.05) 
and mean 24 h salivary cortisol (p=0.02). More interestingly, the well-known association 
between small body size at birth and adult glucose and cortisol metabolism related 
phenotypes were confined to the carriers of haplotype 3; such association was not seen in 
non-carriers (see Table 16). 
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Figure 13. Common haplotypes and their frequencies according to HapMap (H), our study 
(R), and a study by Stevens and co-workers (Stevens et al. 2004) (S). Green boxes 
represent SNPs that differ from the most common haplotype (Hap1). Orange/red boxes 
represent the genotyped SNPs (modified from IV).  
 
Table 16. Serum fasting total cortisol concentration, free cortisol index, and glucose 
tolerance in 65- to 75-year old subjects according to length at birth and GR haplotype 
(modified from IV).  
 GR gene haplotype 3  
Length at birth (cm) Non-carrier Carrier p 
 Total cortisol (nmol/l)  
Lowest third 379 (82) 422 (63) 0.08 
Middle third 376 (91) 395 (55) 0.4 
Highest third   371 (104) 363 (41) 0.7 
p 0.9 0.03  
p for interaction 0.06  
 Free cortisol index*  
Lowest third 8.19 9.31 0.02 
Middle third 8.66 8.77 0.8 
Highest third 8.61 8.38 0.6 
p 0.4 0.02  
p for interaction 0.01  
 Prevalence of impaired glucose tolerance or diabetes (%)  
Lowest third 47  60 0.3 
Middle third 55  42 0.2 
Highest third 50  37 0.1 
p 0.9 0.007  
p for interaction 0.02  
RESULTS AND DISCUSSION 
 80 
 Glucose at 120 min (mmol/l)  
Lowest third 7.7 (77) 8.4 (60) 0.2 
Middle third 7.7 (85) 7.4 (51) 0.7 
Highest third   7.6 (101) 7.3 (38) 0.5 
p 0.9 0.0007  
p for interaction 0.01  
*A measure of free serum cortisol calculated as total serum cortisol/corticosteroid binding globulin. 
 
3.2.2.1 Haplotype specific glucocorticoid receptor mRNA expression 
Since there are no known non-synonymous SNPs in haplotype 3, we assessed whether this 
haplotype affects the regulation, and thereby the expression level of the gene. One silent 
synonymous SNP located in exon 9 alpha (rs6196) tags haplotype 3. We utilized this SNP 
to measure the haplotype specific relative mRNA expression level in human thymus 
samples. The locus, including this tagSNP, was sequenced from three heterozygous 
individuals by using both genomic DNA (after PCR) and cDNA (after RT-PCR) as a 
template. Comparisons of allele peak height ratios of this heterozygous SNP obtained after 
sequencing of cDNA and DNA samples suggested that the expression level of haplotype 3 
was lower than that of the other haplotypes. This quite straight-forward procedure to 
measure allele specific mRNA has also been successfully used in other studies (Pastinen et 
al. 2004, Pastinen and Hudson 2004, Hannula-Jouppi et al. 2005). As there is always 
variation in allele peak height ratios from measurement to measurement, replications are 
needed. In our study, eight replicate measurements per each individual sample were made. 
The mean allele peak height ratio (C/T) for genomic DNA was 0.831 (SD 0.043), whereas 
for cDNA it was 0.777 (SD 0.047). After normalizing the cDNA allelic ratio, by dividing 
it by the genomic DNA allelic ratio, the mRNA expression level of haplotype 3 was 
shown to be 93.7% (95% CI 90.5%-96.8%; p=2.2x10-4) of the expression level of the 
other haplotypes (see Figure 14). 
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Figure 14. A) Sequencing reactions showing the haplotype 3 -specific mRNA expression. 
Arrows show the heterozygous SNP rs6196; allele C (blue) tags the risk haplotype 3. B) 
Boxplot (median, 25th and 75th percentiles, range, outliers) of allele peak height ratios in 
DNA and cDNA samples. 
 
These results suggest that a common GR haplotype may contribute to, and modify the 
association between short length at birth and adult glucose tolerance as well as HPAA 
function, by a mechanism that affects the regulation of GR expression. The slight 
expression level difference suggests that this common haplotype may have some kind of 
effect on mRNA expression level in thymic cells. Additional work is needed to evaluate 
the biological significance of such a small difference. It is also attracting to speculate 
whether the haplotype 3 specific lowered GR mRNA expression level would be more 
pronounced among individuals who were born small. It would also be important to 
measure the haplotype specific mRNA expression level in other human tissues in addition 
to thymus, because several different GR transcripts are transcribed from various, tissue 
specific promoters and the regulation of expression is known to be tissue-specific (Zhou 
and Cidlowski 2005). However, it is obviously problematic to obtain human tissues, such 
as hippocampus and hypothalamus, which would be relevant for the regulation of HPAA. 
Recent studies of allelic variation in human gene expression (Yan et al. 2002, Pastinen et 
al. 2004, Pastinen and Hudson 2004) have suggested that 25% to 50% of genes are 
unequally expressed in an allele specific manner. This is quite a notable number, and 
suggests that studies aimed at the identification of disease susceptibility genes should also 
focus on variations that possibly could affect gene expression rather than only variations 
that would result in changes in the structure of the encoded protein. 
 
DNA cDNA
0,60
0,65
0,70
0,75
0,80
0,85
0,90
0,95
C/
T 
al
le
le
 
pe
ak
 
he
igh
t r
at
io
DNA
cDNA
T/C                           T/C                            T/C
A B
CONCLUSIONS AND FUTURE CHALLENGES 
 82 
CONCLUSIONS AND FUTURE CHALLENGES 
 
Two SNP genotyping platforms based on PCR-RFLP and SNuPeTM were set up at the 
Finnish Genome Center. These techniques proved to be accurate, reliable, and suitable for 
medium-throughput genotyping. However, the development of the genotyping 
technologies has been extremely fast; other modern techniques are thus more efficient for 
high-throughput genotyping.  
 
The nature of genetic studies has changed rapidly during the last few years; the focus has 
moved from monogenic diseases towards complex diseases. This has resulted in an 
increase of association studies compared to linkage studies, and thus in an increased 
number of genotyped samples as well as genetic markers. Pooled genotyping has become 
a popular approach to save effort. Motivation for this approach comes from the 
considerable savings of reagent costs and time; instead of one sample, hundreds of 
samples can be analyzed in parallel at the same time. I have shown in this thesis that 
traditional PCR-RFLP and SNuPeTM genotyping platforms perform, in pooled genotyping, 
as well as the MassArray MALDI-TOF, the platform that has been shown to be accurate in 
pooled genotyping in earlier studies. 
 
In this thesis, the PCR-RFLP and SNuPeTM techniques were used to perform genotyping 
for two separate association studies utilizing large epidemiological cohorts. Among the 
100,000 consecutive pregnancies in Finland during 1997-1998, 34 women had deep 
venous thrombosis, either during pregnancy or puerperium. The Factor V Leiden (FVL) 
polymorphism was shown to increase the pregnancy-associated venous thrombosis risk 
11-fold. FVL interacted with age, BMI, and blood group, increasing the risk alarmingly. 
Due to the low prevalence of FVL, its attributable risk at population level was lower than 
that of the advanced age or higher BMI. 
 
Of the tens of potential candidate genes that have been reported to associate with altered 
glucose or insulin metabolism, only a handful has been replicated in subsequent studies. 
One reason may be that few genetic association studies with late life outcomes have been 
able to incorporate data describing environment early in life. We have shown that the ACE 
insertion/deletion polymorphism and the common GR gene haplotype modify and mediate 
the well-known association between small body size at birth and adult glucose and insulin 
metabolism. Furthermore, our results suggest that there are GR haplotype-specific mRNA 
level differences in human thymus. These findings may reflect gene/environment 
interactions mediated by altered gene expression in response to an adverse environment 
CONCLUSIONS AND FUTURE CHALLENGES 
 83 
before birth. Our results underline the importance of a thorough assessment of such 
interactions in the search for susceptibility genes for common complex disorders. 
   
The association studies of the GR haplotype and the ACE ins/del variation on altered 
glucose metabolism included in this thesis were conducted in the cohort of approximately 
500 people born during 1924-1933 in Helsinki. A future step is to replicate these 
associations in the larger cohort of 2000 individuals born during 1934-1943 in Helsinki, 
for whom detailed birth measurements, current metabolic profile as well as DNA samples 
are already available. It seems that the insertion/deletion polymorphism may not be the 
functional one causing the inter-individual changes in ACE levels. Therefore, the use of 
haplotypes instead of an individual polymorphism in the future replication studies could 
be considered, although the use of this ACE polymorphism is well established. In the 
replication study of the GR gene, the haplotypes in the untranslated regions should also be 
included, since new promoters for GR have been found. 
 
During the six years of work for this thesis, we have very concretely seen the rapid 
development of SNP genotyping techniques. The first projects at the Finnish Genome 
Center were conducted with the PCR-RFLP method, which was soon followed by the 
SNuPeTM method utilizing single primer extension with capillary electrophoresis 
instrument. These techniques have already been replaced by MassArray MALDI-TOF, 
and very recently, with Illumina’s genotyping platform, which will enable the genotyping 
for genome-wide association studies. Nevertheless, these medium-throughput methods 
have allowed interesting studies to be completed and new information to be gained on 
disease associations. 
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